PRODRUGS OF HIV REPLICATION INHIBITING PYRIMIDINES

Abstract: The present invention concerns compounds of the formula (I): (A1)(A2)N-R<1>, the <i>N</i>-oxide forms, the pharmaceutically acceptable addition salts, the quaternary amines and stereochemically isomeric forms thereof, wherein R<1> is substituted C1-6alkyl; -S(=O)-R<8>; -S(=O)2-R<8>; C7-12alkylcarbonyl; optionally substituted C1-6alkyloxycarbonylC1-6alkylcarbonyl; with R<8> being C1-6alkyl, aryl<1> or Het<1>; (A1)(A2)N- is the covalently bonded form of the corresponding intermediate of the formula (A1)(A2)N-H, which is a HIV replication inhibiting pyrimidine of formula (II).

Description: PRODRUGS OF HIV REPLICATION INHIBITING PYR-I TOINES The present invention concerns prodrugs of HIV (Human Immunodeficiency Virus) replication inhibiting pyπmidines. It also relates to their use as a medicine, in particular to their use for the manufacture of a medicament for the treatment of viral infections, to their preparation and compositions compnsmg them. WO 99/50250(JAB 1365) and WO 00/27825(JAB 1425) disclose substituted amino pyπmidine deπvatives having FUN inhibiting properties. EP-B 1-0,270,111 descπbes pyπmidine deπvatives having fungicidal activity. WO 95/10506 concerns N-alkyl-N-aryl-pyπmidinamines including acetonitπle, [[2- bromo-4-(l-methylethyl)phenyl](4,6-dιmethyl-2-pyπmιdιnyl)amιno]-, acetonitπle, [[2-bromo-4-(l-methylethyl)phenyI](4,6-dιmethyl-2-pyπmιdιnyl)amιno]-, monohydrochloπde, 1,2-ethanedιamιne, N-[2-bromo-4-(l-methylethyl)phenyl]-N- (4,6-dιmethyl-2-pyπmιdιnyl)-N',N'-dιethyl; and 1,2-ethanedιamιne, N-[2-bromo-4-(l- methylethyl)phenyl]-N-(4,6-dιmethyl-2-pyπmιdιnyl)-N',N'-dιmethyl. Said compounds are disclosed as antagonists at the CRF (Corticotropin Releasing Factor) receptor and are claimed to have a therapeutic effect on psychiatπc disorders and neurological diseases. The present invention concerns substituted amino pyπmidine deπvatives which differ in structure and pharmacological profile from the pπor art compounds. The present compounds are prodrugs of HIV replication inhibiting compounds. This implies that they are converted after being administered to the subject in need thereof into the coπespondmg pyπmidine-type HTV replication inhibitors per se The present invention concerns a compound of formula (A,)(A 2 )N-R' (I) a N-oxide form, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeπc form thereof, wherein R is Cι- 6 alkyl substituted with cyano, amino, mono- or dι(Cι- alkyl)amιno, nitro, hydroxyCi ι 2 alkyloxy, C| 6 alkyloxyCι ι 2 alkyloxy, Cι-6alkylcarbonyloxyCι )2 alkyloxy, aryl'carbonyloxyCi ι 2 alkyloxy or Het'carbonyloxyCi ι 2 alkyloxy, -S(=O)-R 8 ; -S(=O) -R 8 ; C 7 ι 2 alkylcarbonyl; Cι-6alkyloxycarbonylCι 6 alkylcarbonyl; hydroxycarbonylCi 6 alkylcarbonyl; aryl'Ci 6 alkyloxycarbonylCι 6 alkylcarbonyl, Het'Ci 6 alkyloxycarbonyl- Ci βalkylcarbonyl, R 9 R 10 Ν-Cι- 6 alkyloxycarbonylCι 6 alkylcarbonyl; (Aι)(A 2 )N- is the covalently bonded form of the corresponding intermediate of formula (A (A 2 )N-H, wherein said intermediate of formula (Aι)(A 2 )N-H is a pyrimidine of formula a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein -a'=a 2 -a 3 =a 4 - represents a bivalent radical of formula -CH=CH-CH=CH- (a-1) -Ν=CH-CH=CH- (a-2) -N=CH-N=CH- (a-3) -N=CH-CH=N- (a-4) -N=N-CH=CH- (a-5) n is 0, 1, 2, 3 or 4; and in case -a'=a 2 -a 3 =a 4 - is (a-1), then n may also be 5; each R independently is hydroxy, halo, Cι_6alkyl optionally substituted with cyano or -C(=O)R 6 , C 3 - cycloalkyl, C 2 - 6 alkenyl optionally substituted with one or more halogen atoms or cyano, C 2 - alkynyl optionally substituted with one or more halogen atoms or cyano, Cι-6alkyloxy, Cι-6alkyloxycarbonyl, carboxyl, cyano, aminocarbonyl, nitro, amino, mono- or di(Cι- 6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O) p R 6 , -NH-S(=O) p R 6 , -C(=O)R 6 , -NHC(=O)H, -C(=O)NHNH 2 , -NHC(=O)R 6 ,-C(=NH)R 6 or a radical of formula wherein each Ai independently is N, CH or CR 6 ; and A 2 is NH, O, S or NR 6 ; L is Ci-ioalkyl, C 2 -ιoalkenyl, C 2 -ιoalkynyl, C 3 . 7 cycloalkyl, whereby each of said groups may be substituted with one or two substituents independently selected from * C 3 . 7 cycloalkyl, * indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo, Cι-6alkyl, hydroxy, Cι_6alkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and Cι-6alkylcarbonyl, * phenyl, pyπdyl, pyπmidinyl, pyrazinyl or pyπdazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined for R , or L is -X'-R 3 or -X 2 -Alk-R π wherein R 3 and R π each independently are phenyl, pyπdyl, pyπmidinyl, pyrazinyl or pyπdazinyl, wherein each of said aromatic πngs may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R 2 ; and X 1 and X 2 each independently are -NR 7 -, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)- or -S(=O) 2 -; Q represents hydrogen, Cι- 6 alkyl, halo, polyhaloCι- 6 alkyl or -NR 4 R 5 ; and R 4 and R 5 are each independently selected from hydrogen, hydroxy, Cι-i 2 alkyl, Cι-i 2 alkyloxy, Cι.i2alkylcarbonyl, Cι-i2alkyloxycarbonyl, Ci_i 2 alkylthiocarbonyl, aryl, am o, mono- or dι(Cι-i 2 alkyl)ammo, mono- or dι(Ci-i2alkyl)amιnocarbonyl wherein each of the aforementioned C \ ι 2 alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, Cι- 6 alkyloxy, hydroxyCι- 6 alkyloxy, carboxyl, C]-6alkyloxycarbonyl, cyano, ammo, lmino, mono- or dι(Cι-6alkyl)amιno, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)pR 12 , -NH-S(=O) p R 12 , -C(=O)R 12 , -NHC(=O)H, -C(=O)NHNH 2 , -NHC(=O)R I2 ,-C(=NH)R 12 , aryl and Het; or R 4 and R 5 taken together may form pyrrohdinyl, pipeπdinyl, morphohnyl, azido or mono- or dι(Cι-i2alkyl)amιnoCι- 4 alkanedιyl; R is methyl, amino, mono- or dimethylamino or polyhalomethyl; R 7 is hydrogen; aryl; formyl; Cι-6alkylcarbonyl; Cι-6alkyl; Cι- 6 alkyloxycarbonyl, Cι_6alkyl substituted with formyl, Cι-6alkylcarbonyl, Cj- 6 alkyloxycarbonyl, Ci-6alkylcarbonyloxy; Cι-6alkyloxyCι.6alkylcarbonyl substituted with Ci-6alkyloxycarbonyl; R 8 is d- 6 alkyl, aryl 1 or Het 1 ; R 9 and R 10 each independently are selected from hydrogen, Ci 4 alkyl, amιnoCι- 4 alkyl, mono - or di(Cι- 4 alkyl)amιnoCι- 4 alkyl; or R and R 10 are taken together to form a bivalent radical of formula -CH 2 -CH 2 -Z-CH 2 -CH 2 - with Z being O, NR 13 , CH 2 , or a direct bond; R , 12 is methyl, amino, mono- or dimethylamino or polyhalomethyl; R , 13 i •s hydrogen, amιnoCι- 4 alkyl, mono - or dι(Cι alkyl)amιnoC 1 . alkyl; R , 14 is methyl, amino, mono- or dimethylamino or polyhalomethyl; Y represents hydrogen, hydroxy, halo, Cι- 6 alkyl, C 3 - 7 cycloalkyl, C 2 - alkenyl optionally substituted with one or more halogen atoms, C 2 - alkynyl optionally substituted with one or more halogen atoms, Cι-6alkyl substituted with cyano or -C(=O)R 14 , Cι_6alkyloxy, Cι-6alkyloxycarbonyl, carboxyl, cyano, nitro, am o, mono- or dι(Cι- 6 alkyl)amιno, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, - S(=O) p R 14 , -NH-S(=O) p R 14 , -C(=O)R 14 , -NHC(=O)H, -C(=O)NHNH 2 , -NHC(=O)R 14 ,-C(=NH)R 14 or aryl; p is 1 or 2; aryl 1 is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, Cι-6alkyl, C - 7 cycloalkyl, Cι-6alkyloxy, cyano, nitro, ammo, mono- or polyhaloCi - 6 alkyl and polyhaloCi 6 alkyloxy, aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, Ci-βalkyl, C 3 . 7 cycloalkyl, Cι-6alkyloxy, cyano, nitro, polyhaloCi - 6 alkyl and polyhaloCi - 6 alkyloxy; Het 1 is a saturated, partially saturated or unsaturated (aromatic) heterocychc radical; said saturated heterocychc radical is selected from pyrrohdinyl, pipeπdinyl, homopipeπdinyl, piperazinyl, morpholmyl, tetrahydrofuranyl and tetrahydrothienyl; said partially saturated heterocychc radical is selected from lmidazohnyl, pyrazohnyl, pyrrohnyl, 4,5-dιhydro-oxazolyl, 4,5-dιhydro-thιazolyl, dihydrofuranyl, dihydrothienyl; and said aromatic heterocychc radical is selected from pyπolyl, furanyl, thienyl, lmidazolyl, oxazolyl, thiazolyl, pyπdyl, pyπmidinyl, pyrazinyl and pyπdazinyl wherein each of said aromatic heterocychc radicals may optionally be substituted with C]. alkyl; Het is a saturated, partially saturated or unsaturated (aromatic) heterocychc radical, said saturated heterocychc radical is selected from pyrrohdinyl, pipeπdinyl, homopipeπdinyl, piperazinyl, morpholmyl, tetrahydrofuranyl and tetrahydrothienyl wherein each of said saturated heterocychc radicals may optionally be substituted with an oxo group; said partially saturated heterocychc radical is selected from lmidazohnyl, pyrazohnyl, pyπohnyl, 4,5-dιhydro-oxazolyl, 4,5-dιhydro-thιazolyl, dihydrofuranyl, dihydrothienyl, and said aromatic heterocychc radical is selected from pyrrolyl, furanyl, thienyl, pyπdyl, pyπmidinyl, pyrazinyl and pyπdazinyl wherein each of said aromatic heterocychc radicals may optionally be substituted with hydroxy; provided that acetonitπle, [[2-bromo-4-(l-methylethyl)phenyl](4,6-dιmethyl-2-pyπmιdιnyl)- amino]-, acetonitπle, [[2-bromo-4-(l-methylethyl)phenyl](4,6-dιmethyl-2-pyπmιdιnyl)amιno]- , monohydrochloπde; 1,2-ethanedιamιne, N-[2-bromo-4-(l-methylethyl)phenyl]-N-(4,6-dιmethyl-2- pyπmιdιnyl)-N',N'-dιethyl; 1,2-ethanedιamιne, N-[2-bromo-4-(l-rnethylethyl)phenyl]-N-(4,6-dimethyl-2- pyπrmdιnyl)-N',N'-dιmethyl are not included. The present invention also concerns the use of a compound for the manufacture of a medicament for the prevention or the treatment of HTv * (Human Immunodeficiency Virus) infection, wherein the compound is a compound of formula (A,)(A 2 )N-R 1 (I) a N-oxide form, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeπc form thereof, wherein R 1 is Ci 6 alkyl substituted with cyano, amino, mono- or dι(Cι- alkyl)amιno, nitro, Cι-ι 2 alkyloxy, hydroxy ] 2 alkyloxy, Cι- 6 alkyloxyCι-ι 2 alkyloxy, Cι- 6 alkylcarbonyloxyCι-ι 2 alkyloxy, aryl'carbonyloxyCi-πalkyloxy or Het'carbonyloxyCι-ι 2 alkyloxy; -S(=O)-R 8 , -S(=O) 2 -R 8 ; C 7 ι 2 alkylcarbonyl; Cι- 6 alkyloxycarbonylCι 6 alkylcarbonyl, hydroxycarbonylCι- 6 alkylcarbonyl; aryl'Ci 6 alkyloxycarbonylCι- 6 alkylcarbonyl; Het'Cι- 6 alkyloxycarbonyl- Cι- alkylcarbonyl, R 9 R 10 Ν-C) 6 alkyloxycarbonylCι 6 alkylcarbonyl; (Aι)(A 2 )N- is the covalently bonded form of the coπespondmg intermediate of formula (Aι)(A 2 )N-H, wherein said intermediate of formula (Aι)(A 2 )N-H is a pyπmidine of formula a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeπc form thereof, wherein -a'=a 2 -a 3 =a 4 - represents a bivalent radical of formula -CH=CH-CH=CH- (a-1); -Ν=CH-CH=CH- (a-2); -N=CH-N=CH- (a-3); -N=CH-CH=N- (a-4); -N=N-CH=CH- (a-5); n is 0, 1, 2, 3 or 4; and in case -a'=a 2 -a 3 =a a 4 - is (a-1), then n may also be 5; each R z independently is hydroxy, halo, Cj.galkyl optionally substituted with cyano or -C(=O)R 6 , C 3 - 7 cycloalkyl, C 2 6 alkenyl optionally substituted with one or more halogen atoms or cyano, C 2 - 6 alkynyl optionally substituted with one or more halogen atoms or cyano, Cι-6alkyloxy, Cι-6alkylo ycarbonyl, carboxyl, cyano, aminocarbonyl, nitro, amino, mono- or dι(Cι 6 alkyl)amιno, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O) p R 6 , -NH-S(=O) p R 6 , -C(=O)R 6 , -NHC(=O)H, -C(=O)NHNH 2 , -NHC(=O)R 6 ,-C(=NH)R 6 or a radical of formula wherein each Ai independently is N, CH or CR ; and A 2 is NH, O, S or NR 6 , L is Ci-ioalkyl, C 2 -ιoalkenyl, C 2 10 alkynyl, C 3 - 7 cycloalkyl, whereby each of said groups may be substituted with one or two substituents independently selected from * C 3 . 7 cycloalkyl, * indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo, Cι-6alkyl, hydroxy, Cι-6alkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and Cι-6alkylcarbonyl, * phenyl, pyπdyl, pyπmidinyl, pyrazinyl or pyπdazinyl, wherein each of said aromatic πngs may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined for R ; or L is -X'-R 3 or -X 2 -Alk-R" wherein Alk is Cι- alkanedιyl, R and R ' each independently are phenyl, pyπdyl, pyπmidinyl, pyrazinyl or pyπdazinyl, wherein each of said aromatic πngs may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R 2 , and X 1 and X 2 each independently are -NR 7 -, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)- or -S(=O) 2 -; Q represents hydrogen, Cι- 6 alkyl, halo, polyhaloCι- 6 alkyl or -NR R 5 ; and R 4 and R 5 are each independently selected from hydrogen, hydroxy, Cι-i 2 alkyl, Cι_i2alkyloxy, Cι-i 2 alkylcarbonyl, Cι-i2alkyloxycarbonyl, Ci_i2alkylthiocarbonyl, aryl, amino, mono- or dι(Cι-i2alkyl)amιno, mono- or di(Ci-i2alkyl)amιnocarbonyl wherein each of the aforementioned Cι-ι 2 alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, Cι- 6 alkyloxy, hydroxyCι- alkyloxy, carboxyl, Cι- 6 alkyloxycarbonyl, cyano, amino, imino, mono- or dι(Ci-6alkyl)amιno, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O) p R 12 , -NH-S(=O) p R 12 , -C(=O)R 12 , -NHC(=O)H, -C(=O)NHNH 2 , -NHC(=O)R 12 ,-C(=NH)R 12 , aryl and Het; or R 4 and R 5 taken together may form pyrrohdinyl, pipeπdinyl, morpholinyl, azido or mono- or d^Ci-^alky aminoCi^alkanediyl; R 6 is methyl, amino, mono- or dimethylamino or polyhalomethyl; R 7 is hydrogen; aryl; formyl; Cι-6alkylcarbonyl; Cι_6alkyl; Ci-6alkyloxycarbonyl; Ci-βalkyl substituted with formyl, Ci-6alkylcarbonyl, Cι-6alkyloxycarbonyl, Cι-6alkylcarbonyloxy, Cι- 6 alkyloxyCι- 6 alkylcarbonyl substituted with C i - ό alkyloxycarbonyl , R 8 is Ci 6 alkyl, aryl ' or Het 1 , R 9 and R 10 each independently are selected from hydrogen, amιnoCι- 4 alkyl, R 9 and R 10 are taken together to form a bivalent radical of formula -CH 2 -CH 2 -Z-CH 2 -CH 2 - with Z being O, NR 13 , CH 2 , or a direct bond; 1 "7 R is methyl, amino, mono- or dimethylamino or polyhalomethyl; R 13 is hydrogen, Ci alkyl, mono - or R 14 is methyl, amino, mono- or dimethylamino or polyhalomethyl; Y represents hydrogen, hydroxy, halo, C| 6 alkyl, C 3 7 cycloalkyl, C 2 6 alkenyl optionally substituted with one or more halogen atoms, C 2 6 alkynyl optionally substituted with one or more halogen atoms, Cι-6alkyl substituted with cyano or -C(=O)R 14 , Cι- 6 alkyloxy, Cι- 6 alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or dι(Cι 6 aIkyl)amιno, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, - S(=O) p R 14 , -NH-S(=O) p R 14 , -C(=O)R 14 , -NHC(=O)H, -C(=O)NHNH 2 , -NHC(=O)R 14 ,-C(=NH)R 14 or aryl, p is 1 or 2, aryl 1 is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, Cι.6alkyl, C 3 7 cycloalkyl, Cι-6alkyloxy, cyano, nitro, amino, mono- or dι(Cι alkyl)ammo, polyhaloCi 6 alkyl and polyhaloCi 6 alkyloxy, aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, Ci-6alkyl, C 3 7 cycloalkyl, Cj-όalkyloxy, cyano, nitro, polyhaloCi 6 alkyl and polyhaloCi - 6 alkyloxy; Het is a saturated, partially saturated or unsaturated (aromatic) heterocychc radical; said saturated heterocychc radical is selected from pyπohdinyl, pipeπdinyl, homopipeπdinyl, piperazinyl, morpholmyl, tetrahydrofuranyl and tetrahydrothienyl; said partially saturated heterocychc radical is selected from lmidazohnyl, pyrazohnyl, pyrrohnyl, 4,5-dιhydro-oxazolyl, 4,5-dιhydro-thιazolyl, dihydrofuranyl, dihydrothienyl; and said aromatic heterocychc radical is selected from pyrrolyl, furanyl, thienyl, lmidazolyl, oxazolyl, thiazolyl, pyπdyl, pyπmidinyl, pyrazinyl and pyπdazinyl wherein each of said aromatic heterocychc radicals may optionally be substituted with Het is a saturated, partially saturated or unsaturated (aromatic) heterocychc radical; said saturated heterocychc radical is selected from pyrrohdinyl, pipeπdinyl, homopipeπdinyl, piperazinyl, morpholmyl, tetrahydrofuranyl and tetrahydrothienyl wherein each of said saturated heterocychc radicals may optionally be substituted with an oxo group; said partially saturated heterocychc radical is selected from lmidazohnyl, pyrazohnyl, pyrrohnyl, 4,5-dιhydro-oxazolyl, 4,5-dιhydro-thιazolyl, dihydrofuranyl, dihydrothienyl; and said aromatic heterocychc radical is selected from pyrrolyl, furanyl, thienyl, pyπdyl, pyπmidinyl, pyrazinyl and pyπdazinyl wherein each of said aromatic heterocychc radicals may optionally be substituted with hydroxy As used in the foregoing definitions and hereinafter Cι_ 4 alkyl as a group or part of a group encompasses the straight and branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, butyl and the like; Cι- 6 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as the groups defined for Cι- 4 alkyl and pentyl, hexyl, 2-methylbutyl and the like; C \ ιoalkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 10 carbon atoms such as the groups defined for Ci 6 alkyl and heptyl, octyl, nonyl, decyl and the like; Cι-ι 2 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 12 carbon atoms such as the groups defined for Ci ιoalkyl and undecyl, dodecyl and the like; C 7 ]2 alkyl as a group or part of a group encompasses the straight and branched chain saturated hydrocarbon radicals having from 7 to 12 carbon atoms such as, for example, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, 2-methyl-heptyl, 4-ethyl-nonyl and the like; defines straight or branched chain saturated bivalent hydrocarbon radicals having from 1 to 4 carbon atoms such as methylene, 1,2-ethane- diyl or 1,2-ethyhdene, 1,3-propanedιyl or 1,3-propyhdene, 1,4-butanedιyl or 1 ,4-butyhdene and the like, C 3 7 cycloalkyl is geneπc to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl; C 2 - 6 alkenyl defines straight and branched chain hydrocarbon radicals having from 2 to 6 carbon atoms containing a double bond such as ethenyl, propenyl, butenyl, pentenyl, hexenyl and the like; C 2 -ι 0 alkenyl defines straight and branched chain hydrocarbon radicals having from 2 to 10 carbon atoms containing a double bond such as the groups defined for C 2 - 6 alkenyl and heptenyl, octenyl, nonenyl, decenyl and the like; C 2 6 alkynyl defines straight and branched chain hydrocarbon radicals having from 2 to 6 carbon atoms containing a tπple bond such as ethynyl, propynyl, butynyl, pentynyl, hexynyl and the like; C 2 -ιoalkynyl defines straight and branched chain hydrocarbon radicals having from 2 to 10 carbon atoms containing a tπple bond such as the groups defined for C 2 - 6 alkynyl and heptynyl, octynyl, nonynyl, decynyl and the like As used herein before, the term (=O) forms a carbonyl moiety when attached to a carbon atom, a sulfoxide moiety when attached to a sulfur atom and a sulfonyl moiety when two of said terms are attached to a sulfur atom The term halo is geneπc to fluoro, chloro, bromo and lodo. As used in the foregoing and hereinafter, polyhalomethyl as a group or part of a group is defined as mono- or polyhalosubstituted methyl, in particular methyl with one or more fluoro atoms, for example, difluoromethyl or tπfluoromethyl, polyhaloCi 6 alkyl as a group or part of a group is defined as mono- or polyhalosubstituted Ci 6 alkyl, for example, the groups defined in halomethyl, 1,1-dιfluoro-ethyl and the like. In case more than one halogen atoms are attached to an alkyl group within the definition of polyhalomethyl or polyhaloCi 6 alkyl, they may be the same or different Het or Het are meant to include all the possible isomeπc forms of the heterocycles mmeennttiioonneed in the definitions of Het or Het 1 , for instance, pyrrolyl also includes 2H- pyrrolyl. The Ηet or Ηet 1 radical may be attached to the remainder of the molecule of formula (I) through any πng carbon or heteroatom as appropπate. Thus, for example, when the heterocycle is pyπdyl, it may be 2-pyπdyl, 3-pyπdyl or 4-pyπdyl When any vaπable (eg. aryl, R 2 etc.) occurs more than one time in any constituent, each definition is independent. Lines drawn into πng systems from substituents indicate that the bond may be attached to any of the suitable πng atoms. For therapeutic use, salts of the compounds of formula (I) are those wherein the counteπon is pharmaceutically acceptable. However, salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or puπfication of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention. The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to compπse the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form. The latter can conveniently be obtained by treating the base form with such appropπate acids as inorganic acids, for example, hydrohahc acids, e g. hydrochloπc, hydrobromic and the like; sulfuπc acid; mtπc acid; phosphoπc acid and the like; or organic acids, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoιc, 2-oxopropanoιc, oxalic, malomc, succinic, maleic, fumaπc, malic, tartaπc, 2-hydroxy-l,2,3-propanetπcarboxyhc, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonιc, cyclohexanesulfamic, 2-hydroxybenzoιc, 4-amιno-2-hydroxybenzoιc and the like acids Conversely the salt form can be converted by treatment with alkali into the free base form. The compounds of formula (I) containing acidic protons may be converted into their therapeutically active non-toxic metal or amine addition salt forms by treatment with appropπate organic and inorganic bases. Appropπate base salt forms compπse, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e g. pπmary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, dnsopropylamine, di- n-butylamine, pyπohdine, pipeπdine, morphohne, tπmethylamine, tπethylamine, tπpropylamme, quinuchdine, pyπdine, quinohne and isoquinoline, the benzath e, N- methyl-D-glucamine, 2-ammo-2-(hydroxymethyl)- 1 ,3-propanedιol, hydrabarmne salts, and salts with amino acids such as, for example, arginine, lysme and the like. Conversely the salt form can be converted by treatment with acid into the free acid form. The term addition salt also compπses the hydrates and solvent addition forms which the compounds of formula (I) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like. The term "quaternary amine" as used hereinbefore defines the quaternary ammonium salts which the compounds of formula (I) are able to form by reaction between a basic nitrogen of a compound of formula (I) and an appropπate quatermzing agent, such as, for example, an optionally substituted alkylhahde, arylhahde or arylalkylhahde, e.g. methyhodide or benzyhodide. Other reactants with good leaving groups may also be used, such as alkyl tπfluoromethanesulfonates, alkyl methanesulfonates, and alkyl p- toluenesulfonates A quaternary amine has a positively charged nitrogen. Pharmaceutically acceptable counteπons include chloro, bromo, lodo, tπfluoroacetate and acetate. The counteπon of choice can be introduced using ion exchange resins. It will be appreciated that some of the compounds of formula (I) and their N-oxides, addition salts, quaternary amines and stereochemically isomeπc forms may contain one or more centers of chirahty and exist as stereochemically isomeπc forms. The term "stereochemically isomeπc forms" as used hereinbefore defines all the possible stereoisomeπc forms which the compounds of formula (I), and their N-oxides, addition salts, quaternary amines or physiologically functional deπvatives may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeπc forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure as well as each of the individual isomeπc forms of formula (I) and their N-oxides, salts, solvates or quaternary amines substantially free, i.e. associated with less than 10%, preferably less than 5%, in particular less than 2% and most preferably less than 1% of the other isomers In particular, stereogenic centers may have the R- or S-configuration, substituents on bivalent cyclic (partially) saturated radicals may have either the as- or trαns-configuration Compounds encompassing double bonds can have an E or Z-stereochemistry at said double bond. Stereochemically isomeπc forms of the compounds of formula (I) are obviously intended to be embraced within the scope of this invention The N-oxide forms of the present compounds are meant to compπse the compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the so-called N- oxide. Some of the compounds of formula (I) may also exist in their tautomeπc form. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention Whenever used hereinafter, the term "compounds of formula (I)" is meant to also include their N-oxide forms, their salts, their quaternary amines and their stereochemically isomeπc forms. Of special interest are those compounds of formula (I) which are stereochemically pure. An interesting group of compounds are those compounds of formula (I) wherein the (Aι)(A 2 )Ν- moiety is the covalently bonded form of the corresponding intermediate of formula (A'ι)(A' 2 )N-H, said compounds being represented by formula (A'ι)(A' 2 )N-R 1 (V) wherein said corresponding intermediate of formula (A'ι)(A' 2 )N-H is a pyπmidine of formula a N-oxide, an addition salt, a quaternary amine and a stereochemically isomeπc form thereof, wherein -b'=b 2 -C(R 2a )=b 3 -b 4 = represents a bivalent radical of formula -N=CH-C(R 2a )=N-CH= (b-4) -N=CH-C(R 2a )=CH-N= (b-5) -CH=N-C(R 2a )=N-CH= (b-6) q is 0, 1 , 2; or where possible q is 3 or 4 R 2a is cyano, aminocarbonyl, mono- or dι(methyl)amιnocarbonyl, Cj-6alkyl substituted with cyano, aminocarbonyl or mono- or dι(methyl)amιnocarbonyl, C 2 . alkenyl substituted with cyano, or C 2 . 6 alkynyl substituted with cyano; each R independently is hydroxy, halo, Cj-6alkyl optionally substituted with cyano or -C(=O)R , C 3 - 7 cycloalkyl, C 2 - 6 alkenyl optionally substituted with one or more halogen atoms or cyano, C 2 - 6 alkynyl optionally substituted with one or more halogen atoms or cyano, Cι-6alkyloxy, Cι-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or dι(Cι-6alkyl)amιno, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O) p R 6 , -NH-S(=O) p R 6 , -C(=O)R 6 , -NHC(=O)H, -C(=O)NHNH 2 , -NHC(=O)R 6 ,-C(=NH)R 6 or a radical of formula wherein each A) independently is N, CH or CR 6 ; and R 6 is methyl, amino, mono- or dimethylamino or polyhalomethyl; and L, Y and Q are as defined heremabove for the intermediates of formula (II). A special group of compounds contains those compounds of formula (I) or (F) wherein R 1 is Cι- 6 alkyl substituted with cyano, Cι-ι 2 alkyloxy, hydroxyCι-] 2 alkyloxy, Ci βalkyloxyCi ι 2 alkyloxy or aryl'carbonyloxyC] ι 2 alkyloxy; -S(=O) 2 -R 8 with R 8 being Cι. 6 alkyl, aryl 1 or Het 1 ; C 7 ι alkylcarbonyl; R 9 R 10 N-Cι- 6 alkyloxycarbonylCι- 6 alkyl- carbonyl with R and R 1 each independently being selected from mono - or dι(Cι- 4 alkyl)amιnoCι- 4 alkyl or R 9 and R 10 are taken together to form a bivalent radical of formula -CH 2 -CH 2 -O-CH 2 -CH 2 -. Another special group of compounds contains those compounds of formula (I) or (F) wherein R 1 is Cι. 6 alkyl substituted with cyano, Cι-ι 2 alkyloxy, hydroxyCι-ι alkyloxy, Ci 6 alkyloxyCι ι 2 alkyloxy or aryl'carbonyloxyC) ] 2 alkyloxy. Another special group of compounds contains those compounds of formula (I) wherein one or more, preferably all, of the following restπctions apply in the covalently bonded form of the pyπmidine compound of formula (II) : 0 -a'=a 2 -a 3 =a 4 - is a radical of formula (a-1); n) n is 1, in) R 2 is cyano, preferably in the para position relative to the -NH- group; IV) Y is hydrogen, cyano, -C(=O)NH 2 or a halogen, preferably a halogen; v) Q is hydrogen or -NR R 5 wherein R 4 and R 5 are preferably hydrogen; vi) L is -X-R 3 ; preferably wherein X is NR 7 , O or S, most preferably wherein X is NH, and preferably wherein R 3 is substituted phenyl, most preferably phenyl substituted with one, two or three substituents each independently selected from Ci 6 alkyl, halo and cyano. Another special group of compounds contains those compounds of formula (F) wherein one or more, preferably all, of the following restπctions apply in the covalently bonded form of the pyπmidine compound of formula (II') : 0 -b'=b 2 -C(R 2a )=b 3 -b 4 = is a radical of formula (b-1); n) q is 0; m) R 2a is cyano or -C(=O)NH 2 , preferably R 2a is cyano; IV) Y is hydrogen, cyano, -C(=O)NH 2 or a halogen, preferably a halogen; v) Q is hydrogen or -NR 4 R 5 wherein R 4 and R 5 are preferably hydrogen; vn) L is -X-R 3 ; preferably wherein X is NR 7 , O or S, most preferably wherein X is NH, and preferably wherein R 3 is substituted phenyl, most preferably phenyl substituted with one, two or three substituents each independently selected from Ci 6 alkyl, halo and cyano. An interesting group of compounds are those compounds of formula (I) or (F) wherein L is -X-R 3 wherein R 3 is 2,4,6-tπsubstιtuted phenyl, each substituent independently selected from chloro, bromo, fluoro, cyano or Ci 4 alkyl. Also interesting are those compounds of formula (I) or (F) wherein Y is hydrogen, chloro or bromo and Q is hydrogen or ammo. Particular compounds are those compounds of formula (I) wherein in the formula of the coπesponding pyπmidine of formula (II) -a'=a 2 -a 3 =a 4 - represents a bivalent radical of formula -CH=CH-CH=CH- (a-1), R 2 is 4-cyano and n is 1 Also particular compounds are those compounds of formula (F) wherein in the > 2a. formula of the coπesponding pyπmidine of formula (II') -b =b -C(R )=b -b = rreepprreesseennttss a bivalent radical of formula -CH=CH-C(R 2a )=CH-CH= (b-1), R 2a is cyan and q is 0 Prefeπed compounds are those compounds of formula (I) wherein in the formula of tthhee ccooππeessppoonnddiinngg ppyyππmmiiddiinnee ooff ffoorrmmuullaa ((IIII)) --aa''==aa 22 --aa 33 ==aa 44 -- rreepprreesseennttss aa bbiivvaalleenntt radical of ffocrmula -CH=CH-CH=CH- (a-1), R 2 is 4-cyano and n is 1, L is -X-R 3 wwhheerreeiinn R 3 is a 2,4,6-tπsubstιtuted phenyl, Y is hydrogen or halo and Q is hydrogen or NH 2 . Also prefeπed compounds are those compounds of formula (F) wherein in the formula of the coπesponding pyπmidine of formula (IF) -b'=b 2 -C(R 2a )=b -b 4 = represents a bivalent radical of formula -CH=CH-C(R 2a )=CH-CH= (b-1), R 2a is cyano and q is 0, L is -X-R 3 wherein R 3 is a 2,4,6-tπ substituted phenyl, Y is hydrogen or halo and Q is hydrogen or NH 2 . Most preferred compounds of formula (I) or (F) are those compounds wherein the corresponding pyπmidme compound of formula (II) or (IT) is- 4-[[4-amιno-5-chloro-6-[(2,4,6-tπmethylphenyl)amιno]-2-pyπmιdιnyl]amιno]- benzonitπle; 4-[[5-chloro-4-[(2,4,6-tπmethylphenyl)amιno]-2-pyπmιdιnyl]amιno]benzonιtπle; 4-[[5-bromo-4-(4-cyano-2,6-dιmethylphenoxy)-2-pyπmιdιnyl]amιno]benzomtπle; 4-[[4-amιno-5-chloro-6-[(4-cyano-2,6-dιmethylphenyl)amιno]-2-pyπmιdιnyl]ammo]- benzonitπle; 4-[[5-bromo-6-[(4-cyano-2,6-dιmethylphenyl)amιno]-2-pynmιdιnyl]amιno]benzo- nitπle; 4-[[4-amιno-5-chloro-6-(4-cyano-2,6-dιmethylphenyloxy)-2-pyπmιdιnyl]amιno]- benzonitπle; 4-[[4-amιno-5-bromo-6-(4-cyano-2,6-dιmethylphenyloxy)-2-pyπmιdιnyl]amιno]- benzonitπle; 4-[[4-[(2,4,6-tπmethylphenyl)amιno]-2-pyπmιdιnyl]amιno]benzomtπle; and 4-[[2-[(4-cyanophenyl)amιno]-4-pyπmιdιnyl]amιno]-3,5-dιmethylbenzonιtπle; the N-oxides, the addition salts, the quaternary amines and the stereochemically isomeπc forms thereof In general, compounds of formula (I) can be prepared by reacting an HIV replication inhibiting intermediate of formula (A|)(A 2 )Ν-H with an intermediate of formula (HI), wherein Wi represents a suitable leaving group, such as a halogen, e.g. chloro, bromo and the like, in the presence of a suitable base, such as for example sodium hydπde, butyl lithium, sodium hydroxide or N-(l-methylethyl)-2-propanamιne, and a suitable reaction-inert solvent, such as for example tetrahydrofuran. (Aι)(A 2 )Ν H + R^W, ► (A ! )(A 2 )N R 1 OH) (I) In this and the following preparations, the reaction products may be isolated from the reaction medium and, if necessary, further puπfied according to methodologies generally known in the art such as, for example, extraction, crystallization, distillation, tπturation and chromatography Compounds of formula (I), wherein R 1 is Cι- 6 alkyloxycarbonylCι 6 alkylcarbonyl, aryl Cι- 6 alkyloxycarbonylCι- 6 alkylcarbonyl, Het'Cι- 6 alkyloxycarbonylCι- 6 alkylcarbonyl or R 9 R 10 N-Cι- 6 alkyloxycarbonylCι 6 alkylcarbonyl, said R 1 being represented by R la -O-C(=O)-C] 6 alkyl-C(=O), and said compounds by formula (I-a), can be prepared by reacting an HTV replication inhibiting intermediate of formula (Aι)(A 2 )N-H with an intermediate of formula (IN), wherein W 2 represents a suitable leaving group, such as a halogen, e.g. chloro, bromo and the like, and an intermediate of formula (N) in the presence of a suitable base, such as sodium hydride, and a suitable reaction-inert solvent, such as NN-dimethylformamide. o o (A 1 )(A 2 )Ν— H + W 2 — C— C r6 alkyl C— W 2 + R 1a -OH (IV) (V) (l-a) The compounds of formula (I) may further be prepared by converting compounds of formula (I) into each other according to art-known group transformation reactions. Compounds of formula (I), wherein R 1 is hydroxyCι-ι 2 alkyloxyC]- 6 alkyl, said compounds being represented by formula (I-b), can be prepared by hydrolyzing a compound of formula (I), wherein R 1 is Cι- 6 alkyl substituted with Cι-6alkylcarbonyl- oxyCι-ι 2 alkyloxy, aryl'carbonyloxyCι_ι 2 alkyloxy or Het'carbonyloxyCι-ι 2 alkyloxy, said R 1 being represented by R lb -C(=O)-O-Cι-ι 2 alkyloxyCι- 6 alkyl, and said compounds being represented by formula (I-c), in the presence of a suitable hydrolysing agent, such as a suitable alkali metal hydroxide or an earth alkaline metal, such as lithium hydroxide, and a suitable reaction-inert solvent, such as tetrahydrofuran and water. o (A 1 )(A 2 )N— C r6 alkyloxyC,- 12 alkyI-0-C — R lb ► (A 1 )(A 2 )N— C r6 alkyIoxyC rl2 alkyl-OH (l-c) (l-b) The compounds of formula (I) may be converted to the corresponding N-oxide forms following art-known procedures for converting a trivalent nitrogen into its N-oxide form. Said N-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboper- oxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarbo- peroxoic acid, peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. t.butyl hydro-peroxide. Suitable solvents are, for example, water, lower alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents. Some of the compounds of formula (I) and some of the intermediates in the present invention may contain an asymmetric carbon atom. Pure stereochemically isomeric forms of said compounds and said intermediates can be obtained by the application of art-known procedures. For example, diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter cuπent distribution, liquid chromatography and the like methods. Enantiomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or compounds by, for example, selective crystallization or chromatographic techniques, e.g. liquid chromatography and the like methods; and finally converting said separated diastereomeric salts or compounds into the coπesponding enantiomers. Pure stereochemically isomeric forms may also be obtained from the pure stereochemically isomeric forms of the appropriate intermediates and starting materials, provided that the intervening reactions occur stereospecifically. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) and intermediates involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase. Some of the intermediates and starting materials are known compounds and may be commercially available or may be prepared according to art-known procedures or may be prepared according to the procedures described in WO99/50250 and WO 00/27825. In general, the HTV replication inhibiting pyrimidine derivatives of formula (II) can be prepared by reacting an intermediate of formula (VI) wherein W 3 is a suitable leaving group such as, for example, a halogen, hydroxy, triflate, tosylate, thiomethyl, methyl- sulfonyl, trifluoromethylsulfonyl and the like, with an amino derivative of formula (VET) optionally under solvent-free conditions or in a reaction-inert solvent such as, for example, ethanol, l-methyl-2-pyrrolidinone, NN-dimethylformamide, 1,4- 01/85699 -18- dioxane, tetrahydrofuran, dimethyl sulfoxide, tetraline, sulfolane, acetonitrile and the like, under a reaction-inert atmosphere such as, for example, oxygen free argon or nitrogen, and optionally in the presence of an acid such as, for example, 1 N hydrochloπc acid in diethyl ether or the like. This reaction can be performed at a temperature ranging between 50°C and 250°C. (VI) (Vϋ) (ID The HIV replication inhibiting pyπmrdine intermediates of formula (II), wherein L is a radical of formula -NR 7 R 3 , said intermediates being represented by formula (Il-a), can be prepared by reacting an intermediate of formula (VHI) wherein W is a suitable leaving group such as, for example, a halogen or a triflate, with an intermediate of formula (IX) under solvent-free conditions or in an appropriate solvent such as, for example, ethanol, l-methyl-2-pyπolidinone, N,N-dimethylformamιde, 1,4-dioxane, tetrahydrofuran, dimethyl sulfoxide, tetraline, sulfolane, acetonitπle and the like, under a reaction-inert atmosphere such as, for example, oxygen free argon or nitrogen, and optionally in the presence of an acid such as, for example, 1 Ν hydrochloπc acid in diethyl ether. This reaction can be performed at a temperature ranging between 50°C and 250°C. The HTV replication inhibiting pyπmidine intermediates of formula (II), wherein L is a radical of formula -O-R , said intermediates being represented by formula (Il-b), can be prepared by reacting an intermediate of formula (VHI) wherein W is a suitable leaving group such as, for example a halogen or a triflate, with an intermediate of formula (X) in an appropπate solvent such as, for example, 1,4-dioxane, dimethyl sulfoxide, tetraline, sulfolane and the like under a reaction-inert atmosphere such as, for example, oxygen free argon or nitrogen, and in the presence of a base such as, for example, sodium hydride, potassium hydride, sodium hydroxide or the like. This reaction can be performed at a temperature ranging between 50°C and 250°C. The HTV replication inhibiting pyπmidine intermediates of formula (II) may further be prepared by converting intermediates of formula (II) into each other according to art-known group transformation reactions. The HIV replication inhibiting pyπmidine intermediates of formula (Et) may be converted to the coπesponding N-oxide forms following art-known procedures as descπbed hereinabove for the preparation of the Ν-oxide forms of the compounds of formula (I). For instance, the HTV replication inhibiting pyrimidine intermediates of formula (II) wherein Q is a halogen may be converted to the coπesponding intermediates wherein Q is -ΝR 4 H using NH R 4 as a reagent in a reaction inert solvent such as, for example, 1,4-dioxane and the like, optionally in the presence of a suitable base such as, for example, N,N-diethylethanamine or NN-diisopropylethylamine or the like. In case R 4 contains a hydroxy moiety, it may be convenient to perform the above reaction with a protected form of ΝH 2 R whereby the hydroxy moiety bears a suitable protecting group P being, for instance, a tπalkylsilyl group, and subsequently removing the protective group according to art-known methodologies. Intermediates of formula (VI) wherein L is -X-R 3 , said intermediates being represented by formula (VI- 1) can be prepared by reacting a pyrimidine derivative of formula (XI) wherein each W is as defined previously, with HXR 3 (XII) in a reaction-inert solvent such as, for example, 1,4-dioxane, 2-propanol or the like, and in the presence of a base such as, for example, N,N-diethylethanamine or NN- diisopropylethylamine or the like. Different regio-specific isomers may be formed and can be separated from one another using suitable separation techniques such as, for example, chromatography. (XI) (XII) (VI- 1) Intermediates of formula (VIII) can be prepared by reacting an intermediate of formula (Xl-a) wherein W 4 is a suitable leaving group such as, for example, a halogen, with an intermediate of formula (XfU) in a suitable solvent such as, for example, l-methyl-2-pyrrohdιnone, 1,4-dioxane or the like, in the presence of an acid such as, for example, 1 N hydrochloπc acid in diethyl ether. This reaction can be performed at a temperature ranging between 50°C and 250°C (VIII) Alternatively, intermediates of formula (VTA) can be prepared by reacting an intermediate of formula (XTV) with a leaving group introducing agent, wherein W 4 represents the leaving group and R represents the remaining of the leaving group introducing agent, examples of suitable leaving group introducing agents are phosphorous oxychloπde, tπflic anhydπde or a functional deπvative thereof under a reaction-inert atmosphere such as, for example, oxygen free argon or nitrogen This reaction can be performed at a temperature ranging between 20°C and 150°C Intermediates of formula (XTV) can be prepared by reacting an intermediate of formula (XV) or a functional deπvative thereof, with an intermediate of formula (Xπi) This reaction may be performed under solvent-free conditions or in an appropπate solvent such as, for example, diglyme, tetraline or the like under a reaction-inert atmosphere such as, for example, oxygen free argon or nitrogen, and optionally in the presence of a base such as, for example, sodium hydπde, potassium hydπde or the like. This reaction can be performed at a temperature ranging between 100°C and 250°C. Intermediates of foπnula (XTV) can also be prepared by reacting an intermediate of formula (XNI), wherein W 5 is a suitable leaving group such as for example Cι- 6 alkyloxy and Y and Q are as defined for an intermediate of formula (II), with an intermediate of formula (XVII) in an appropπate solvent such as , for example, ethanol, or the like, and in the presence of a base such as, for example, sodium ethoxide or the like, under a reaction-mert atmosphere such as, for example, oxygen free argon or nitrogen. The reaction can be performed at a temperature ranging between 20°C and 125°C. (XVI) (XVπ) (XIV) A convenient way of prepaπng an intermediate of formula (VHI) wherein Y is a bromine or chloro atom, said intermediates being represented by formula (VITI-1), involves the introduction of a bromine or chloro atom to an intermediate of formula (XVHI), wherein W is as previously defined, using N-bromosuccinimide or N-chlorosuccinimide in a reaction-inert solvent such as, for example, chloroform, carbon tetrachloπde or the like. This reaction can be performed at a temperature ranging between 20°C and 125°C. Analogous to the conversion of intermediates of formula (IT) wherein Q is a halogen to intermediates of formula (II) wherein Q is -NHR 4 , the intermediates of formula (VI), (VrJT) and (XI) can also be converted. The compounds of formula (I) as prepared in the hereinabove described processes may be synthesized as a mixture of stereoisomeric forms, in particular in the form of racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I) may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the coπesponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials. It will be appreciated by those skilled in the art that in the processes described above the functional groups of intermediate compounds may need to be blocked by protecting groups. Functional groups which it is desirable to protect include hydroxy, amino and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl groups (e.g. tert-butyldimethylsilyl, tert-butyldiphenylsilyl or trimethylsilyl), benzyl and tetrahydropyranyl. Suitable protecting groups for amino include tert-butyloxycarbonyl or benzyloxycarbonyl. Suitable protecting groups for carboxylic acid include Cj. 6 alkyl or benzyl esters. The protection and deprotection of functional groups may take place before or after a reaction step. The use of protecting groups is fully described in 'Protective Groups in Organic Chemistry', edited by J W F McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis' 2 nd edition, T W Greene & P G M Wutz, Wiley Interscience (1991). As descπbed hereinabove, the compounds of the present invention are prodrugs. Prodrugs are pharmacologically acceptable deπvatives of drugs per se. After administration to the subject in need thereof, the prodrugs undergo a conversion to the physiologically active species This conversion may mvolve an enzymatic or chemical cleavage of a functionality on the prodrug, thus resulting in the release of the corresponding active compound. The reference by Goodman and Gilman (The Pharmacologrcal Basis of Therapeutics, 8 th ed., McGraw-Hill, Int. Ed. 1992, "Biotransformation of Drugs", p. 13-15) descπbing prodrugs generally, is hereby incorporated. The present compounds hydrolyse under physiological conditions releasing the coπesponding HTV replication inhibiting (reverse transcπptase inhibitors) pyπmidine deπvatives of formula (13) or (IF) The advantage of prodrugs is that they may provide an increased bioavailabihty than that which could be obtained if the active compound per se was administered; a delayed bioavailabihty; an enhanced distπbution into targeted tissues or an increased biological penetration into a given biological system (e.g. blood, lymphatic system, central nervous sytem); an altered metabolism and rate of excretion; an increased solubility. An increased solubility may allow administration by injection or by solution, the latter especially being preferred when the patients are children, elderly people or persons with difficulties to swallow An increased solubility may enhance the bioavailabihty, and may also contπbute to an improvement of the drug load per unit dosage form, which may reduce the patient's pill burden and hence improve the patient compliance. It may also provide for the possibility to increase the daily administered amount of drug. Due to their conversion under physiological conditions into the HTV replication inhibiting pyπmidines of formula (II) or (IF), the present compounds show antiretroviral properties, in particular against Human Immunodeficiency Virus (HTV), which is the aetiological agent of Acquired Immune Deficiency Syndrome (AIDS) in humans. The HTV virus preferentially infects human T-4 cells and destroys them or changes their normal function, particularly the coordination of the immune system. As a result, an infected patient has an everdecreasing number of T-4 cells, which moreover behave abnormally Hence, the rmmunological defense system is unable to combat infections and neoplasms and the HTV infected subject usually dies by opportunistic infections such as pneumonia, or by cancers. Other conditions associated with HIV infection include thrombocytopaenia, Kaposi's sarcoma and infection of the central nervous system characterized by progressive demyelination, resulting in dementia and symptoms such as, progressive dysarthria, ataxia and disorientation. TON infection further has also been associated with peripheral neuropathy, progressive generalized lymphadenopathy (PGL) and AEDS-related complex (ARC). The present compounds also show activity against multi drug resistant HTV strains, in particular multi drug resistant HTV-1 strains, more in particular the present compounds show activity against HTV strains, especially HTV-1 strains, that have acquired resistance to art-known non-nucleoside reverse transcriptase inhibitors. Art- known non-nucleoside reverse transcriptase inhibitors are those non-nucleoside reverse transcriptase inhibitors other than the active species of the prodrugs of the present invention. They also have little or no binding affinity to human α-1 acid glycoprotein. Due to their conversion into compounds having antiretroviral properties, particularly anti-HTV properties, especially anti-HTV-1 -activity, the compounds of formula (I) or (F), their N-oxides, pharmaceutically acceptable addition salts, quaternary amines and stereochemically isomeric forms thereof, are useful in the treatment or prevention of viral infections. In general, the compounds of the present invention may be useful in the treatment of warm-blooded animals infected with viruses whose existence is mediated by, or depends upon, the enzyme reverse transcriptase. Conditions which may be prevented or treated with the compounds of the present invention, especially conditions associated with HIV and other pathogenic retroviruses, include AIDS, AEDS-related complex (ARC), progressive generalized lymphadenopathy (PGL), as well as chronic CΝS diseases caused by retroviruses, such as, for example HIV mediated dementia and multiple sclerosis. The present compounds of formula (I) or (F) or any subgroup thereof may therefore be used as medicines, especially against above-mentioned conditions. They may be used in the manufacture of a medicament for the treatment or the prevention of the above-mentioned conditions. Said use as a medicine or method of treatment comprises the systemic administration to HTV-infected subjects of an amount effective to combat the conditions associated with HTV and other pathogenic retroviruses, especially HTV-1. In view of the utility of the compounds of formula (I) or (F), there is provided a method of treating warm-blooded animals, including humans, suffering from or a method of preventing warm-blooded animals, including humans, to suffer from viral infections, especially HIN infections. Said method comprises the administration, preferably oral administration, of an effective amount of a compound of formula (I) or (F), a N-oxide form, a pharmaceutically acceptable addition salt, a quaternary amine or a possible stereoisomeric form thereof, to warm-blooded animals, including humans. The present invention also provides compositions for treating viral infections comprising a therapeutically effective amount of a compound of formula (I) or (F) and a pharmaceutically acceptable carrier or diluent. The compounds of the present invention or any subgroup thereof may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable earner, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for percutaneous administration, the earner optionally compπses a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleteπous effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for prepaπng the desired compositions. These compositions may be administered in vaπous ways, e.g., as a transdermal patch, as a spot-on, as an ointment. The compounds of the present invention may also be administered via inhalation or insufflation by means of methods and formulations employed in the art for administration via this way. Thus, in general the compounds of the present invention may be administered to the lungs in the form of a solution, a suspension or a dry powder. Any system developed for the delivery of solutions, suspensions or dry powders via oral or nasal inhalation or insufflation are suitable for the administration of the present compounds. It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical earner. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositoπes, injectable solutions or suspensions and the like, and segregated multiples thereof. Since the present compounds are prodrugs, which have to be converted into the active compounds per se, it will be appreciated that their dose to be administered will be such as to release an effective therapeutic or prophylactic amount of the active compound per se upon conversion. As used hereinbefore or hereinafter, a therapeutically effective amount of a compound of formula (I) or (F) will define such an amount of a compound of formula (I) or (F) which enables the release of a therapeutically effective amount of the coπesponding active compound per se upon conversion. In general it is contemplated that an effective daily amount of the coπesponding HTV replication inhibiting pyπmidine deπvative per se would be from 0.01 mg/kg to 50 mg/kg body weight, more preferably from 0.1 mg/kg to 10 mg/kg body weight. It may be appropπate to administer the required dose as two, three, four or more sub-doses at appropπate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 1 to 1000 mg, and in particular 5 to 200 mg of active ingredient per unit dosage form. The exact dosage and frequency of administration depends on the particular compound of formula (I) or (F) used, the particular condition being treated, the seventy of the condition being treated, the age, weight and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescπbing the compounds of the instant invention The effective daily amount ranges mentioned hereinabove are therefore only guidelines and are not intended to limit the scope or use of the invention to any extent The present prodrugs can be used alone or in combination with other therapeutic agents, such as anti-virals, antibiotics, immunomodulators or vaccines for the treatment of viral infections They may also be used alone or in combination with other prophylactic agents for the prevention of viral infections The present compounds may be used in vaccines and methods for protecting individuals against viral infections over an extended peπod of time. The prodrugs may be employed in such vaccines either alone or together with other compounds of this invention or together with other anti-viral agents in a manner consistent with the conventional utilization of reverse transcπptase inhibitors in vaccines Thus, the present compounds may be combined with pharmaceutically acceptable adjuvants conventionally employed in vaccines and admrnistered in prophylactically effective amounts to protect individuals over an extended penod of time against H1N infection The combination of an antiretroviral compound and a compound of formula (I) or (F) can be used as a medicine Thus, the present invention also relates to a product containing (a) a compound of formula (I) or (F), and (b) another antiretroviral compound, as a combined preparation for simultaneous, separate or sequential use in anti-HTV treatment The different drugs may be combined in a single preparation together with pharmaceutically acceptable earners. Said other antiretroviral compounds may be known antiretroviral compounds such as suramrne, pentamidme, thymopentm, castanospermme, dextran (dextran sulfate), foscarnet-sodium (tπsodium phosphono formate), nucleoside reverse transcπptase inhibitors, e.g. zidovudine (3'-azιdo-3'-deoxythymτdιne, AZT), didanos e (2',3'-dιdeoxyιnosιne; ddl), zalcitabine (dideoxycytidine, ddC) or lamivudine (2'-3'-dideoxy-3'-thiacytidine, 3TC), stavudine (2',3'-didehydro-3'-deoxythymidine, d4T), abacavir and the like; non- nucleoside reverse transciptase inhibitors such as nevirapine (l l-cyclopropyl-5,l l-di- hydro-4-methyl-6H-dipyrido[3,2-b : 2',3'-e][l,4]diazepin-6-one), efavirenz, delavirdine, TMC-120, TMC-125 and the like; compounds of the TTBO (tetrahydro- imidazo[4,5,l-jk][l,4]-benzodiazepine-2(lH)-one and thione)-type e.g. (S)-8-chloro- 4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo- [4,5,l-jk][l,4]benzodiazepine-2(lH)-thione; compounds of the α-APA (α-anilino phenyl acetamide) type e.g. α-[(2-nitrophenyl)amino]-2,6-dichlorobenzene-acetamide and the like; inhibitors of trans-activating proteins, such as TAT-inhibitors, e.g. RO-5-3335, or REV inhibitors, and the like; protease inhibitors e.g. indinavir, ritonavir, saquinavir, lopinavir (ABT-378), nelfinavir, amprenavir, TMC-126, BMS- 232632, VX-175 and the like; fusion inhibitors, e.g. T-20, T-1249, AMD-3100 and the like; inhibitors of the viral integrase; nucleotide reverse transcriptase inhibitors, e.g. tenofovir and the like; ribonucleotide reductase inhibitors, e.g. hydroxyurea and the like. By administering the compounds of the present invention with other anti-viral agents which target different events in the viral life cycle, the therapeutic effect of these compounds can be potentiated. Combination therapies as described above exert a synergistic effect in inhibiting TON replication because each component of the combination acts on a different site of ΗIV replication. The use of such combinations may reduce the dosage of a given conventional anti-retroviral agent which would be required for a desired therapeutic or prophylactic effect as compared to when that agent is administered as a monotherapy. These combinations may reduce or eliminate the side effects of conventional single anti-retroviral therapy while not interfering with the anti-viral activity of the agents. These combinations reduce potential of resistance to single agent therapies, while minimizing any associated toxicity. These combinations may also increase the efficacy of the conventional agent without increasing the associated toxicity. The prodrugs of the present invention may also be administered in combination with immunomodulating agents, e.g. levamisole, bropirimine, anti-human alpha interferon antibody, interferon alpha, interleukin 2, methionine enkephalin, diethyldithiocarbamate, tumor necrosis factor, naltrexone and the like; antibiotics, e.g. pentamidine isethiorate and the like; or cholinergic agents, e.g. tacrine, rivastigmine, donepezil, galantamine and the like to prevent or combat infection and diseases or symptoms of diseases associated with ΗTV infections, such as AIDS and ARC, e.g. dementia. A compound of formula (I) or (F) can also be combined with another compound of formula (I) or (F). Although the present invention focuses on the use of the present compounds for preventing or treating HTV infections, the present compounds may also be used as inhibitory agents for other viruses which depend on similar reverse transcnptases for obligatory events in their life cycle. Expeπ mental part In the below descπbed preparations of intermediate compounds and final compounds, HPLC stands for high performance liquid chromatography A. Preparation of the intermediate compounds Example Al Reaction under argon atmosphere. A solution of 2,4,6-tπmethylbenzenamιne (0.00461 mol) m 1,4-dioxane (5 ml) was added to a solution of 5-bromo-2,4-dichloro- pyπrmdine (0.00439 mol) in 1,4-dioxane (5 ml) N,N-bis(l-methylethyl)ethanamine (0.00548 mol) was added. The reaction mixture was stiπed and refluxed for 20 hours. The solvent was evaporated. The residue was dissolved in ethyl acetate, washed with a saturated aqueous sodium bicarbonate solution, water and bπne, dned with sodium sulfate, filtered, and the solvent was evaporated The residue was puπfied by column chromatography over silica gel (eluent: 1:5, 1 2 and 1: 1 CH 2 C1 2 . hexane). Two pure fraction groups were collected and their solvent was evaporated, yielding 0.35 g (24%) of 5-bromo-4-chloro-N-(2,4,6-tπmethylphenyl)-2-pyπmιdιnamme (interm. 1) and 0.93g (65%) of 5-bromo-2-chloro-N-(2,4,6-tπmethylphenyl)-4-pyπmιdιnamιne (interm. 2). Example A2 a) 4-Hydroxy-5-chloro-2-methylthιopyπmιdιne (0 0156 mol) and 4- amrnobenzonitπle (0.078-mol) were combined as a melt and stirred at 180-200°C for 6 hours. The reaction mixture was cooled, and tnturated sequentially with boiling CH 2 C1 2 and CH 3 CΝ to obtain 95% pure compound, which was dned, yielding 1.27 g (33%) of 4-[(5-chloro-4-hydroxy-2-pyπmιdιnyl)amιno]benzonιtπle (interm. 3; mp. >300°C). b) POCl 3 (10 ml) was added to intermediate (3) (0 0028 mol). The flask was equipped with a condenser and heated to 80°C for 35 minutes. The material was quenched on ice and the resulting precipitate was collected and washed with water (50 ml). The sample was dned. A fraction thereof was further punfied by column chromatography. The pure fractions were collected and the solvent was evaporated, yielding 4-[(4,5-dιchloro-2-pyπmιdιnyl)amιno]benzonιtπle (interm. 4) c) The mixture of intermediate (4) (0.0132 mol) in tetrahydrofuran (75 ml) and CH 2 C1 2 (10 ml) was stirred for 15 minutes. HC1 m diethyl ether (0.0145 mol) was added slowly, and the mixture was stiπed for 5 minutes. The solvent was removed under reduced pressure, yielding 3.98 g of 4-[(4,5-dιchloro-2- pyπmιdιnyl)amιno]benzomtπle monohydrochlonde (interm. 5) Example A3 a)2,4,5,6-tetrachloropynmιdιne (0.0134 mol), 1,4-dioxane (30 ml), 2,4,6-tnmethyl aniline (0.0134 mol), and NN-bιs(l-methylethyl)ethanamιne (0 0136 mol) were added to a flask under argon and stirred at 55 °C for 16 hours. The solvent was evaporated, and the residue was dissolved in CH 2 C1 2 , then puπfied by column chromatography over silica gel (eluent: CH 2 Cl 2 /hexane 1/4, and 1/2). The desired fractions were collected and their solvent was evaporated, yielding 0.15 g 4,5,6- tnchloro-N-(2,4,6-tnmethylphenyl)-2-pyπmιdιnamιne (interm. 6) and 3.15 g 2,5,6- tπchloro-N-(2,4,6-tπmethylphenyl)-4-pyπmιdmamιne (interm. 7) b) A mixture of intermediate 7 (0.00474 mol) in ΝH 3 , (2 0 M in 2-propanol, 20 ml) was heated in a pressure vessel at 75-80°C for 40 hours. The temperature was increased to 110-115°C. The solvent was evaporated to produce 1.85 g of residue. The sample was heated with NH 3 (0.5 M in 1,4-dioxane; 20 ml) at 125°C for 18 hours The solvent was evaporated, yielding 1.7 g of a mixture of two isomers, i.e. 2,5-dιchloro- N4-(2,4,6-tπmethylphenyl)-4,6-pyπmιdιnedιamιne (interm 8) and 5,6-dιchloro-N4- (2,4,6-tnmethylphenyl)-2,4-pyπmιdιnedιamιne (interm 9) Example A4 a) A mixture of 4-[(l,4-dιhydro-4-oxo-2-pyπmιdιnyl)amιno]benzonιtnle, (0.12 mol) in POCl 3 (90 ml) was stirred and refluxed under Argon for 20 minutes. The reaction mixture was slowly poured onto 750 ml ice/water, and the solid was separated by filtration. The solid was suspended in 500 ml water, and the pH of the suspension was adjusted to neutral by adding a 20% ΝaOH solution The solid was again separated by filtration, suspended in 200 ml 2-propanone, and 1000 ml CH 2 C1 2 was added. The mixture was heated until all solid had dissolved. After cooling to room temperature, the aqueous layer was separated, and the organic layer was dned. Dunng removal of the drying agent by filtration, a white solid formed in the filtrate Further cooling of the filtrate m the freezer, followed by filtration, yielded 21.38 g (77.2%) of 4-[(4-chloro-2-pyπmιdιnyl)amιno]benzonιtπle (interm. 10) b) Intermediate (10) (0.005 mol), l-bromo-2,5-pyrrohdιnedιone (0.006 mol) and trichloromethane (10 ml) were combined in a sealed tube and heated at 100°C overnight. The reaction mixture was allowed to cool to room temperature. Silica gel (2 g) was added, and the solvent was evaporated. The residue was puπfied by flash column chromatography over silica gel (eluent: CH 2 Cl 2 /hexane 9/1). The pure fractions were collected and the solvent was evaporated, yielding 1.31 g (84.5%) of 4-[(5-bromo-4-chloro-2-pyπmιdιnyl)amιno]benzonιtnle (interm. 11). Example A5 To a flask under argon was added 4-amιno-2,5,6-tnchloropyπmιdιne (0.08564 mol), 4-amτno-benzonιtnle (0.1071 mol), l-methyl-2-pyπohdιnone (17 ml) and HC1 in diethylether (IM; 85 6 ml). The mixture was placed in an oil bath at 130 °C under a stream of nitrogen until the ether was gone. An additional 10 ml of l-methyl-2- pyrrohdinone was added. The mixture was heated at 145 °C for 16 hours under argon. 1,4-Dιoxane was added. The mixture was refluxed, cooled, then filtered. The filtrate was evaporated. The residue was dissolved in CH 2 C1 2 , washed with 1 N NaOH, then filtered. The solid was dissolved in 2-propanone, evaporated onto silica gel, and chromatographed using 1-3% 2-propanone in hexane as eluent. The pure fractions were collected and the solvent was evaporated, yielding 1.63 g (6.8%) of 4- [(4-amιno-5,6-dιchloro-2-pyπmιdιnyl)amιno]benzonιtnle (interm. 12). Example A6 a) To a flask under argon containing intermediate (1) (0 00107 mol) was added ether. To this homogeneous solution was added HCl/diethylether (IM; 0.00109 mol). The solvent was evaporated and 1,4-dioxane (35 ml) and 4-amιnobenzonιtπle (0.00322 mol) were added The reaction mixture was stirred and refluxed for 4 days. The solvent was evaporated The residue was dissolved in CH 2 C1 2 , washed with a saturated sodium bicarbonate solution, dned, filtered and the solvent was evaporated to give 0.79 g of amber oil. The oil was punfied by reverse phase HPLC. The desired fractions were collected and the solvent was evaporated, yielding residues 1 and 2. Residue 1 was puπfied by column chromatography over silica gel (eluent: 0 and 2% CH 3 OH:CH 2 Cl 2 ) The pure fractions were collected and the solvent was evaporated, yielding 0.0079 g (2.0%) of 4-[[5-chloro-2-[(2,4,6-tπmethylphenyl)amιno]-4- pyπmidιnyl]amιno]benzonιtnle (interm. 13). Residue 2 was punfied by column chromatography over silica gel (eluent: 0 and 2% CH 3 OH:CH 2 Cl 2 ). The pure fractions were collected and the solvent was evaporated, yielding 0.0044 g (1.0%) of 4-[[5-bromo-2-[(2,4,6-tπmethylphenyl)ammo]-4- pyπmrdιnyl]amιno]benzomtπle (interm 14) b) To a flask containing intermediate 2 (0.00285 mol) was added ether. To this homogeneous solution was added HC1 in diethyl ether (IM; 0.00855 mol). The solvent was evaporated and 1,4-dioxane (20 ml) was added. Finally, 4-ammobenzonιtπle (0.00291 mol) and 1,4-dioxane (15 ml) were added and the reaction mixture was stirred and refluxed for seven days. The solvent was evaporated, the residue dissolved in CH C1 2 , washed with 1 M NaOH, and the solvent evaporated. The residue was dissolved in CH 2 C1 2 (10 ml) and the precipitate was filtered off and dned, yielding 0.15g (13%) of 4-[[5-bromo-4-[(2,4,6-tnmethylphenyl)amιno]-2-pyπmιdιnyl]amιno]benzonιtnle (interm. 15). 4-[[4-[(2,4,6-tnmethylphenyl)amιno]-2-pyπmιdιnyl]amιno]benzonιtnle (interm. 16) was prepared according to an analogous procedure. Example A7 a) A 3: 1 mixture of intermediate (8) and intermediate (9) [as prepared in example A3b] and 4-amιnobenzonιtnle (0.01422 mol) was heated in a pressure vessel at 180°C for 5 hours. The sample was partitioned between CH 2 C1 2 and diluted NaHCO 3 , dned over K 2 CO 3 , filtered, and evaporated. CH 3 CN was stirred in, the resulting precipitate removed by filtration. The filtrate was further puπfied by reverse phase HPLC. The pure fractions were collected and the solvent was evaporated, yielding 0.17 g of 4-[[4-amιno-5-chloro-6-[(2,4,6-tπmethylphenyl)amιno]-2- pyπmιdιnyl]amιno]benzonιtnle tnfluoroacetate (1.1) (interm. 17) Example A8 HC1 in diethylether (IM; 0.0045 mol) was added to a suspension of intermediate (4) (0.003 mol) in 1,4-dioxane (5 ml), stiπed under argon in a sealable tube The mixture was warmed to evaporate the diethylether, and 2,4,6-tnmethylbenzenamιne (0 009 mol) was added. The tube was sealed, and the reaction mixture was heated to 150°C for 12 hours. The reaction mixture was allowed to cool to room temperature Sequentially, silica gel (2.2 g) and CH 3 OH (50 ml) were added After evaporating the solvent, the residue was punfied by flash chromatography (eluent gradient. CH 2 Cl 2 :CH 3 OH: NttiOH 99.5: 0.45: 0.05 up to 99: 0.9: 0.1). The pure fractions were collected and the solvent was evaporated. The residue was dned , yielding 0 80 g (73.4%) of 4-[[5-chloro-4-[(2,4,6-tπmethylphenyl)amιno]-2- pynmιdιnyl]amιno]benzonιtπle (interm. 18) 4-[[2-[(4-cyanophenyl)amιno]-4- pynmιdιnyl]amιno]-3,5-dιmethylbenzonιtπle (interm. 19) was prepared according to an analogous procedure. Example A9 A mixture of intermediate (5) (0.0025 mol) and 2,6-dιbromo-4-methylbenzenamιne (0.0075 mol) in 1,3-dιoxane (5 0 ml) in a sealed tube under argon was heated and stirred at 160°C for 16 hours. The reaction mixture was concentrated by rotary evaporation onto silica gel (2 0 g). The mateπal was punfied by flash chromatography (eluent 1:1 hexane: CH 2 C1 2 ; neat CH 2 C1 2 ; 0.5%, 1% (10%NH4OH in CH 3 OH) in CH 2 C1 2 ) for 90% punty. Recrystalhzation yielded 0.15 g (12.2%) of 4- [[5-chloro-4-[(2,6-dιbromo-4-methylphenyl)amιno]-2-pyπmιdιnyl]amιno]benzomtπle (interm. 20; 95 % punty). Example A 10 NaH (0.0075 mol; 60% suspension in oil) was added to a suspension of 2,4,6- tπmethylphenol (0.0075 mol) in 1,4-dioxane (5 ml) in a sealable tube under argon. The mrxture was stirred for 15 minutes, and intermediate (4) (0.0025 mol) was added. The tube was sealed, and the reaction mixture was heated to 150°C for 15 hours The reaction was allowed to cool to room temperature. After silica gel (2.0 g) was added, the solvent was evaporated. The residue was puπfied by flash column chromatography over silica gel (eluent gradient: CH 2 C1 2 : hexane 9:1 up to 100:0; then 100: 0: 0 up to 97: 2.7: 0.3). The pure fractions were collected and the solvent was evaporated The residue was dned, yielding 0 73 g of (80.2%) 4-[[5-chloro-4-(2,4,6-tnmethylphenoxy)-2-pyπmιdιnyl]amιno] benzomtnle (interm. 21) Example Al l NaH, 60% suspension in oil (0 003 mol) and l-methyl-2-pyπohdιnone (3 ml) were added to a suspension of 4-hydroxy-3,5-dιmethylbenzonιtnle (0.003 mol) in 1,4- dioxane (3 ml) in a sealable tube under argon. After the H 2 had evolved, intermediate (11) (0.001 mol) was added The tube was sealed and the reaction mrxture was heated to 160°C for 16 hours The mixture was cooled to room temperature, transfeπed to a beaker and diluted with methanol (20 ml) Water (200 ml) was added dropwise. The aqueous mixture was extracted with CH 2 Cl 2 /CH 3 OH 90/10 (3 x 300 ml). The organic layer was separated, dned, filtered and adsorbed onto silica gel (1 g). The solvent was evaporated and the residue was punfied by flash column chromatography over silica gel (eluent: CH 2 Cl 2 /CH 3 OH/NH 4 OH from 100/0/0 to 98/1.8/0.2). The desired fractions were collected and the solvent was evaporated. The residue was tnturated with hot CH 3 CN, filtered off, then dned, yielding 0.20 g (47 6%) of 4-[[5-bromo-4-(4- cyano-2,6-dιmethylphenoxy)-2-pynmιdιnyl]amιno]benzonιtπle (interm. 22) Example A12 To a pressure vessel under argon was added intermediate 12 (0.00286 mol), 4-cyano- 2,6-dιmethylanιhne (0.00571 mol), IM HC1 in diethyl ether (0.00140 mol) and 1,4-dιoxane (8 ml). The reaction mixture was heated in an oil bath under a stream of nitrogen until all the solvents had evaporated. 1 -methyl -2-pyrrolιdιnone (3 ml) was added, and the reaction mixture was heated at 220-240 °C for 3 hours. Heating was continued at 210-220 °C for 6 hours. The residue was dissolved in 1,4-dioxane, evaporated, partitioned between CH 2 C1 2 and 1 N NaOH, filtered, organic layers were dned with potassium carbonate and evaporated. The desired compound was isolated and punfied by preparative reverse phase chromatography. The pure fractions were collected and the solvent was evaporated, yielding 0.0165 g (1.1% after lyophihzation) of 4-[[4-amιno-5-chloro-6-[(4-cyano-2,6-drmethylphenyl)amιno]-2- pynmιdιnyl]amιno]benzonιtπle tπfluoroacetate (1:1) (interm. 23). Example A13 A mixture of intermediate (11) (0.0011 mol), 2,6-dιmethyl-4-(2-propyl)benzenamιne (0 0011 mol), N,N,N',N'-tetramethyl-l,8-naphthalenedιamιne (0.0022 mol) and 1 M HC1 in ether (2.3 ml) (0.0023 mol) in 1,4-dioxane (25 ml) was stirred and heated to 95°C for 16 hours. Solvent was removed by rotary evaporation and the residue was punfied by reverse phase preparatory HPLC. The combined fractions containing the desired matenal were lyophihzed to yield 0.23g of (48%); mp 198-201 °C (interm. 24) Example A 14 N,N-dι(methylethyl)ethanamιne (0 0024 mol) was added to 4-amιno-2,6-dιmethyl- 3,4-benzonιtnle (0 00219 mol) and 4-[[(5-bromo-4,6-dιchloro)-2-pyπrmdιnyl]amιno]- benzomtnle (0 00218 mol) The reaction vial was sealed and heated to 155-160 °C with stirring for 1 5 days The sample was cooled to room temperature. The sample was treated with flash column chromatography over silica gel (eluent: CH 2 C1 2 ). Puπftcation was completed through preparative HPLC to yield 0.05g of 4-[[5-bromo- 4-chloro-6-[(4-cyano-2,6-dιmethylphenyl)amιno]-2-pynmιdιnyl]amιno]benzonιtnle (5.0%), mp. 259-260°C (interm 25) Example A15 Sequentially 2,4,6-tnmethylbenzenarnιne (0.0022 mol) and NN-dι(methylethyl)- ethanamme (0.0024 mol) were added to a solution of 4-[[(5-bromo-4,6-dιchloro)-2- pynmιdιnyl]amιno]benzonιtπle (0.00218 mol) in 1,4-dioxane (10 ml). The tube was sealed and the suspension was heated to 120-130°C in an oil bath while stirnng for 90 hours. The mrxture was cooled to room temperature. More NN-dr(methylethyl)- ethanamine (15 ml) was added, and the sample was reheated to 120-130 °C for 64 hours. The reaction was heated at 150°C for 6 days. The sample was cooled to room temperature. The sample was diluted with ethylacetate and extracted with cold IM ΝaOH. The aqueous phase was backwashed with ethylacetate. The combined organic phases were dned and concentrated. Flash column chromatography over silica gel (eluent: CH 2 C1 2 ). The sample was further punfied by preparatory HPLC to yield 0.53g of 4-[[5-bromo-4-chloro-6-[(2,4,6-tnmethylphenyl)amιno]-2- pynmιdιnyl]amιno]benzonιtnle (54.9%); mp. 220-221°C (interm. 26). Example A 16 A mixture of 4-amιnobenzomtπle (0.0043 mol) and (0.0021mol) in 1,4-dioxane (30 ml) was stiπed at 100°C for 16 hours. The solvent was removed by rotary evaporation. The solid residue was tπturated and the residue was dned in vacuo at 40°C for 16 hours, yielding 0.452 g of (55%); mp. >300°C (interm. 27) Example A17 To a pressure vessel was added (0.00567 mol), 4-amιnobenzonιtπle (0.01163 mol) and l-methyl-2-pyrτohdιnone (20 ml). The reaction mixture was heated at 140 °C for 16 hours. The reaction mixture was cooled to room temperature and acetonitπle and water were added. The resulting precipitate was filtered, and the solid recrystalhzed with acetonitnle to give 1.27 g of 4-[[5- bromo-4-(4-cyano-2,6-dιmethylphenoxy)-6-methyl-2-pynmrdιnyl]amιno]benzonιtnle (52); mp. 260-262°C (interm. 28). Example A18 Intermedrate (11) (0.001 mol) and 2,6-dιmethyl-4-amιnobenzonιtnle (0.00473 mol) were combined and heated to 150°C while stirπng for 16 hours. The sample was dissolved in CH 3 OH and evaporated onto silica gel (1 g) and eluted with 1:1 hexane: CH 2 C1 2 , 4: 1 CH 2 Cl 2 :hexane, and neat CH 2 C1 2 (2 L). The desired fractions were evaporated and the residue was dned in vacuo for 16 hours at 45°C. The thus obtained residue was transferred to a 4 ml vial in CH 2 C1 2 and the solvent was evaporated, yielding 0.120 g of 4-[[5-bromo-6-[(4-cyano-2,6-dιmethylphenyl)amιnoJ- 2-pynmιdιnyl]amιno]benzonιtπle (28.6%); mp. 277-280°C (interm. 29). Example A 19 4-[[5-bromo-4-(4-cyano-2,6-dιmethylphenoxy)-6-chloro-2-pynmιdιnyl]amιno]- benzonitπle (0.00250 mol) and NH 3 / 1,4-dioxane 0 5M (0 015 mol) were heated in a pressure vessel at 150°C for 4 days The sample was allowed to sit at ambient conditions for 2 days. Water was added slowly to the mixture until a precipitate formed. The mixture was stiπed for 2 hours and filtered. The solid was recrystalhzed from CH 3 CN to obtain 0.58 g (fraction 1). The filtrate was evaporated (fraction 2). Both fractions were combined and puπfied by column chromatography, eluting with CH 2 C1 2 The resulting residue of the desired fraction was recrystalhzed from CH 3 CN to yield 0 44 g of 4-[[4-amιno-5-bromo-6-(4-cyano-2,6-dιmethylphenyloxy)-2- pyπmιdιnyl]amιno]benzonιtnle (40 5%). The sample was dned at 80°C for 16 hours at 0 2 mm Hg (interm. 30) 4-[[4-amιno-5-chloro-6-(4-cyano-2,6- dιmethylphenyloxy)-2-pynmιdιnyl]amιno]benzonιtπle (interm. 31) was prepared according to an analogous procedure Example A20 4-[[5-bromo-4-(4-cyano-2,6-dιmethylphenoxy)-6-chloro-2-pynmιdιnyl]amιno]- benzomtnle (0 000660 mol), tetrahydrofuran (1 ml), and 1-pyπohdιneethanamιne (0.00198 mol) were added to a pressure vessel. The mixture was heated at 75°C for 16 hours CH 2 C1 2 was added, and the mixture was washed with water, dned, filtered and the filtrate was evaporated. Punfication using flash column chromatography eluting with 1 9 methanol methylene chlonde produced a solid which was redissolved in CH 3 CN. HCl/diethylether 1.0M (0.48 ml) was added, and the mixture was cooled in ice. Filtration yielded 0 19 g of 4-[[5-bromo-4-(4-cyano-2,6-dιmethylphenoxy)-6- [(l-pyπolιdιnyl)ethylamιno]-2-pyπmιdmyl]amιno]benzonιtnle hydrochloπde (1:1) (50 6%); mp. 208-210°C (interm. 32). Example A21 To a pressure vessel was added 4-[[5-bromo-4-(4-cyano-2,6-dιmethylphenoxy)-6- chloro-2-pynmιdιnyl] amino] benzomtnle (0 00064 mol), tetrahydrofuran (3 ml), O-methylhydroxylamine (0.06 g), tetrahydrofuran and NaOH IN (0.00067 mol). The reaction mixture was stirred for 3 days at room temperature, then for 1 day at 75 °C, for 1 day at 90°C and for 2 days at 110°C. To O-methylhydroxylamine (0.60 g) was added tetrahydrofuran (4 ml) and NaOH 50% (0.00719 mol). The liquid was decanted into the reaction flask and the reaction mixture was heated at 110 °C for 3 days. The solvent was evaporated. The residue was dissolved in CH 2 C1 2 , washed with a saturated NaHCO 3 solution and water, dned (Na 2 SO 4 ), filtered and the solvent was evaporated. The residue was punfied by column chromatography over silica gel (eluent: CH 2 C1 2 / CH 3 OH 98/2). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from CH 3 CN, filtered off and dned, yielding 0.15 g of 4-[[5-bromo-4-(4-cyano-2,6-dιmethylphenoxy)-6-(methoxyamιno)- 2-pyπmιdιnyl]amιno]benzonιtnle (51%); mp. 185-186°C The sample was dned (0.2 mm Hg, 80°C, 16 hours) (interm. 33) Example A22 A mixture of of 4-[[5-amιno-4-(4-cyano-2,6-dιmethylphenoxy)-2-pyπmιdιnyl]amιno]- benzonitπle (0.00147 mol) in ethanoic acid anhydnde (10 ml) and 2-propanone (10 ml) was stirred at room temperature for 16 hours The mixture was then heated to 55°C, and more ethanoic acid anhydπde (3 ml) was added The mixture was removed from heat after 18 hours and stiπed for 6 days at room temperature. The sample was concentrated by rotary evaporation to a solid Puπftcation by column chromatography (eluting with 0, 0.5, 1, 1 5, 2% (10% NϋiOH in CH OH ) m methylene chlonde) yielded > m P 290-295°C The solid was dned in vacuo for 16 hours at 60°C (interm 34) Example A23 A mixture of 4-[[4-(4-cyano-2,6-dιmethylphenoxy)-5-nιtro-2-pynrmdιnyl]amιno]- benzomtnle (0.0005 mol) in tetrahydrofuran (20 ml) was hydrogenated overnight with Pd/C 10% (0.100 g) as a catalyst. After uptake of H 2 (3 equiv; 0.0015 mol), the catalyst was filtered off and the filtrate was concentrated by rotary evaporatron and dned in vacuo over 16 hours at 40°C, yielding 0 15 g of 4-[[5-amιno-4-(4-cyano-2,6- dimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile (84%); mp. >300°C (interm. 35). Example A24 4-[[4-[(2,4,6-trimethylphenyl)amino]-5-nitro-2-pyrimidinyl]amino]benzonitrile (0.001 mol), Pd C 10% (0.025 g), ethanol (20 ml), and hydrazine (0.030 mol) were combined to form a slurry and stiπed at room temperature for 16 hours. The solvent was removed by rotary evaporation. The residue was taken up in tetrahydrofuran (20 ml) and methanol (1 ml). A second portion of hydrazine (0.5 g) was added, and the reaction was stirred for 16 hours at room temperature. A third portion of hydrazine (0.5 ml) was added and the reaction was stirred for an additional 16 hours at room temperature. The sample was concentrated by rotary evaporation onto silica gel (1 g) and purified by flash chromatography (eluent: 0.5, 1,2 % 10% (NH4OH in CH 3 OH) in CH 2 C1 2 ). The desired fractions were purified by preparatory HPLC to yield 0.24 g of 4-[[5-arnino-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile (70%); mp. 224-225°C (interm. 36). Example A25 Intermediate (15) (0.001 mol), trimethyl silaneacetylene (0.0012 mol), Pd(PPh 3 ) 2 Cl 2 (0.020 g), Cul (0.010 g) and CF 3 COOH/H 2 O (3 ml) were combined in a sealed tube and heated to 110°C for 10 hours. Second portions of the catalysts Pd(PPh 3 ) 2 Cl 2 (0.020 g) and Cul (0.010 g), and CF 3 COOH/H 2 O (3 ml) were added and the reaction mixture was stirred for 10 hours at 110°C. The material was concentrated by rotary evaporation. The residue was purified by preparative reversed-phase HPLC. The desired fractions were concentrated and purified by reversed-phase preparative HPLC and dried with a stream of N 2 , then in vacuo at 40°C for 16 hours. Yield: 0.011 g of 4-[[5-ethynyl-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile; mp. 165-175°C (interm. 37). Example A26 Intermediate (15) (0.000906 mol), tributylphenyl stannane (0.000906 mol), Pd(PPh 3 ) 4 (0.002718 mol), and 1,4-dioxane (3 ml) were combined under N 2 in a sealed tube and heated to 110°C for 16 hours. The reaction mixture was cooled and concentrated by rotary evaporation. The sample was purified by Preparatory Reverse Phase HPLC, then dried under argon stream. Drying in vacuo yielded 0.0845 g of or 4-[[5-phenyl- 4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile; mp. 209-214°C (interm. 38). Example A27 Intermediate (15) (0.001 mol), tetraethenyl stannane (0.22 ml), 1,4-dioxane (2 ml) and Pd(PPh ) (0.112 g) were combined in a sealed tube under argon. The mixture was stiπed and heated to 100°C for 16 hours. More tetraethenyl stannane and Pd(PPh 3 ) 4 were added. The reaction was placed under argon, stirred and heated. The reaction was concentrated by rotary evaporation and purified on preparative HPLC. The material was dried with a N stream, and dried under vacuum for 4 hours at 60°C to obtain 0.422g of 4-[[5-ethenyl-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]- amino]benzonitrile; mp. 237-242°C (interm. 39). Example A28 Intermediate (15) (0.001225 mol), CuCN (0.001470 mol) and NN-dimethylformamide (2 ml) were combined in a sealed tube under argon, then stiπed and heated to 160°C for 16 hours. The residue was purified by column chromatography (eluent: CH 2 Cl 2 /hexane 1/1, then pure CH 2 C1 2 ). The desired fractions were collected and the solvent was evaporated. The residue was triturated under CH 2 C1 2 at room was dried (vacuum, 40°C, 24 hours, yielding 0.0864 g of (24%); mp. 254-259°C (interm. 40). B. Preparation of the final prodrugs Example Bl a) The preparation of (compound 1) To a flask under argon was added NaH 60% and tetrahydrofuran. The reaction was stiπed at room temperature for 10 minutes and intermediate (22) was added. After stirring for 1 hour (chloromethoxy)ethane was added. The reaction mixture was stiπed at room temperature for another 16 hours and the solvent was evaporated to give 2.76 g of a white solid. The solid was dissolved in acetonitrile/methylene chloride and evaporated onto 36 g of silica gel. A flash chromatography eluting with 10% and 20% ethyl acetate: hexane gave a white solid. The solid was dissolved in methylene chloride and chromatographed on silica gel eluting with 1:1 and 2:1 CH 2 Cl 2 :hexane. One recrystallization with acetonitrile gave 0.47g (19%) of compound 1 as a white solid; mp. 181-182°C. b) The preparation of (compound 2) n-Butyl lithium (0.010 mol) was added to a solution of N-(l-methylethyl)-2- propanamine (0.010 mol) in tetrahydrofuran (300 ml), stirred at 0°C. After stirring cold for 30 minutes, (interm. 22) (0.005 mol) was added. The resulting mixture was stirred cold for 15 minutes at which point bromoacetonitrile (0.015 mol) was added and the temperature was allowed to rise to room temperature and the reaction mixture was stirred for 3 days which drove the reaction to 50% completion. Quenched with 0.5 ml H 2 O, the sample was concentrated by rotary evaporation onto silica gel, and purified by flash chromatography (Biotage Flash 40M, eluting with 0, 0.5, 1% (10% NH 4 OH in CH 3 OH) in CH 2 C1 2 ). Preparatory HPLC purification eluting into tubes containing lmmol NaHCO 3 effected final purification. Lyophilized material was taken up in water/CH 2 Cl 2 (1:1 50ml total) and separated. The aqueous layer was extracted 2 more times with 25ml CH 2 C1 . The organic layers were combined and dried over sodium sulfate and rotary evaporated to white solid dried in vacuo at 65°C for 18 hours. Yield: 0.10 g (9%)of compound 2; mp. 205-210°C. Example B2 The preparation of (compound 3) To a homogeneous solution of (0.00162 mol), prepared according to Example Bla, tetrahydrofuran (8 ml) and H O (2 ml), was added LιOH.H 2 O (0.00178 mol). The reaction mixture was stiπed at room temperature for 4 days, the solvent evaporated, the solid dissolved in methylene chlonde, the solution filtered and the filtrate chromatographed on silica gel eluting with 0 and 1% methanol: methylene chlonde to give 0.87 g of a white solid. Two re-crystallizations with acetomtnle gave 0.39 g (48.7%) of compound 3; mp. 199-200°C. Example B3 The preparation of (compound 4) A suspension of (interm. 22) (0.0020 mol) m N, N - dimethylformamide (40 ml) was treated with 0.24 g NaH in one portion. The effervescent mixture was stiπed for 90 minutes to yield a bπght yellow suspension. A mixture of Cl-C(=O)-(CH 2 ) 2 -C(=O)-Cl (0.020 mol) in N, N -dimethylformamide (10 ml) was prepared at -60 °C in a dry ice/ 2-propanol bath. Via cannula, the resultant of the above suspension was transfeπed to the cold solution of Cl-C(=O)-(CH 2 ) 2 -C(=O)-Cl dropwise over 20 minutes. The mixture was warmed to room temperature and stiπed for 3 days. The reaction mixture was cooled in an ice bath and 4-morphohne ethanol (0.063 mol) was added dropwise over 15 minutes. The reaction mixture was returned to room temperature and after 18 hours poured into ether and treated with saturated ΝaHCO 3 . The layers were separated and the aqueous fraction was extracted 3 times with ether and the combined ether extracts were backwashed 5 times with water and dned over MgSO 4 . Concentration yielded 1.07 g of a waxy residue that was subjected to reverse phase preparative HPLC. Lyophihzation of the appropnate fractions provided 0.14 g (9.4%) of compound 4; mp. 84-85°C. Table 1 lists the compounds that were prepared according to one of the above Examples Table 1 C. Pharmacological example The pharmacological activity of the present compounds was examined using the following tests. Example C.l The metabolism of the present compounds was studied in subcellular liver fractions (12000 xg) of rat, dog or human. The compounds were incubated at a final protein concentration of 30 μM; incubations were performed up to 120 minutes at a final protein concentration equivalent to 1 mg/ml microsomal proteins. Reactions were stopped by the addition of an equal volume (2 ml) of N, N-dimethylsulfoxide. Samples were stored at <-18°C until analysis. The anti-HTV activity (IC5 0 ) of the incubates was determined by the assay described below as Example C.2 and the anti- HTV activity after incubation was compared with said activity pnor to incubation (also determined with the assay descnbed below). Table 2 lists IC50 values pnor to and after incubation in subcellular liver fractions. Example C.2 A rapid, sensitive and automated assay procedure was used for the in vitro evaluation of anti-HTV agents. An HTV-1 transformed T4-cell line, MT-4, which was previously shown (Koyanagi et al., Int. J. Cancer, 36, 445-451, 1985) to be highly susceptible to and permissive for HTV infection, served as the target cell line. Inhibition of the EQN- mduced cytopathic effect was used as the end point. The viability of both HTV- and mock-infected cells was assessed spectrophotometπcally via the in situ reduction of 3-(4,5-dιmethylthιazol-2-yl)-2,5-dιphenyltetrazohum bromide (MTT). The 50% cytotoxic concentration (CC50 in μM) was defined as the concentration of compound that reduced the absorbance of the mock-infected control sample by 50%. The percent protection achieved by the compound in HTV-infected cells was calculated by the following formula : (OD T ) HΓV - (ODCJHJV (OD MOCK - COD^H T v expressed in %, whereby (OD- T HJV 1S tne optical density measured with a given concentration of the test compound in HTV-infected cells; (OD c ) Hrv is the optical density measured for the control untreated HTV-infected cells; (OD Q ) MOCK is the optical density measured for the control untreated mock-infected cells; all optical density values were determined at 540 nm The dose achieving 50% protection according to the above formula was defined as the 50% inhibitory concentration (IC 50 in μM) Table 2

Claims: Claims 1. A compound of formula (A,)(A 2 )N-R' (I) a N-oxide foπn, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeπc foπn thereof, wherein R 1 is Cι- 6 alkyl substituted with cyano, amino, mono- or dι(Cι 4 alkyl)amιno, nitro, Cι- 12 alkyloxy, hydroxyCι-ι 2 alkyloxy, Cι- 6 alkyloxyCι j 2 alkyloxy, Cι- 6 alkylcarbonyloxyCι-ι 2 alkyloxy, aryl'carbonyloxyCι-ι 2 alkyloxy or Het'carbonyloxyCi-^alkyloxy; -S(=O)-R 8 , -S(=O) 2 -R 8 ; C 7 ι 2 alkylcarbonyl; Cι- 6 alkyloxycarbonylCι- 6 alkylcarbonyl; hydroxycarbonylC] 6 alkylcarbonyl; aryl'Ci- 6 alkyloxycarbonylCi- alkylcarbonyl; Het'Ci 6 alkyloxycarbonyl- Cι- 6 alkylcarbonyl; R 9 R 10 Ν-Cι 6 alkyloxycarbonylCι 6 alkylcarbonyl; (Aι)(A 2 )N- is the covalently bonded form of the corresponding intermediate of formula (Aι)(A 2 )N-H, wherein said intermediate of formula (Aj)(A 2 )N-H is a pyπmidine of formula a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeπc form thereof, wherein -a =a -a =a - represents a bivalent radical of formula -CH=CH-CH=CH- (a-1), -Ν=CH-CH=CH- (a-2), -N=CH-N=CH- (a-3), -N=CH-CH=N- (a-4), -N=N-CH=CH- (a-5); n is 0, 1 ι , 2, 31 o _ ^ .r.4 Λ -; a n r n.dΛ i . Φn. c n a n „se_-. -a 1 =a „2 -a 3 =a 4 - is (a-1), then n may also be 5, each R , 2 independently is hydroxy, halo, Cι.6alkyl optionally substituted with cyano or -C(=O)R , C 3 - 7 cycloalkyl, C 2 6 alkenyl optionally substituted with one or more halogen atoms or cyano, C 2 6 alkynyl optionally substituted with one or more halogen atoms or cyano, Cι_6alkyloxy, Cι-6alkyloxycarbonyl, carboxyl, cyano, aminocarbonyl, nitro, am o, mono- or dι(Cι alkyl)amιno, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O) p R 6 , -NH-S(=O) p R 6 , -C(=O)R 6 , -NHC(=O)H, -C(=O)NHNH 2 , -NHC(=O)R 6 ,-C(=NH)R 6 or a radical of formula wherein each Ai independently is N, CH or CR 6 ; and A 2 is NH, O, S or NR 6 ; L is Ci-ioalkyl, C 2 -ιoalkenyl, C 2 -ιoalkynyl, C 3 - cycloalkyl, whereby each of said groups may be substituted with one or two substituents independently selected from * C 3 - 7 cycloalkyl, * indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo, Ci-βalkyl, hydroxy, Cι_6alkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and Cι_6alkylcarbonyl, * phenyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined for R 2 ; or L is -X'-R 3 or -X 2 -Alk-R π wherein R and R 11 each independently are phenyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R 2 ; and X 1 and X 2 each independently are -NR 7 -, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)- or -S(=O) 2 -; Q represents hydrogen, Cι- alkyl, halo, polyhaloCi - 6 alkyl or -NR 4 R 5 ; and R 4 and R 5 are each independently selected from hydrogen, hydroxy, Ci.^alkyl, Cι-i2alkyloxy, Cι-i2alkylcarbonyl, Cι,i 2 alkyloxycarbonyl, Cι-i 2 alkylthiocarbonyl, aryl, amino, mono- or di(Cι-i 2 alkyl)amino, mono- or di(Cι-i 2 alkyl)aminocarbonyl wherein each of the aforementioned Cι-ι 2 alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, Cι.6alkyloxy, hydroxyCι- 6 alkyloxy, carboxyl, Cι- 6 alkyloxycarbonyl, cyano, amino, imino, mono- or di(Cι_6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O) p R 12 , -NH-S(=O) p R 12 , -C(=O)R 12 , -NHC(=O)H, -C(=O)NHNH 2 , -NHC(=O)R 12 ,-C(=NH)R 12 , aryl and Het; or R 4 and R 5 taken together may form pyrrohdinyl, piperidinyl, morpholinyl, azido or mono- or di^i-^alky aminoC alkanediyl; R is methyl, amino, mono- or dimethylamino or polyhalomethyl; R 7 is hydrogen; aryl; formyl; Cι_6alkylcarbonyl; Ci-6alkyl; Cι_6alkyloxycarbonyl; Cι_6alkyl substituted with formyl, Ci-6alkylcarbonyl, Cι.6alkyloxycarbonyl, Cι-6alkylcarbonyloxy; Cι-6alkyloxyCι_6alkylcarbonyl substituted with C i -6alkyloxycarbonyl ; R 8 is C,- 6 alkyl, aryl 1 or Het 1 ; R 9 and R 10 each independently are selected from hydrogen, mono - or di(Cι- alkyl)aminoCι- 4 alkyl; or R 9 and R 10 are taken together to form a bivalent radical of formula -CH 2 -CH 2 -Z-CH 2 -CH 2 - with Z being O, NR 13 , CH 2 , or a direct bond; R 12 is methyl, amino, mono- or dimethylamino or polyhalomethyl; R 13 is hydrogen, mono - or di(Cι- 4 alkyl)aminoCι- 4 alkyl; R 14 is methyl, amino, mono- or dimethylamino or polyhalomethyl; Y represents hydrogen, hydroxy, halo, Cι- 6 alkyl, C 3 - 7 cycloalkyl, C 2 - 6 alkenyl optionally substituted with one or more halogen atoms, C 2 - 6 alkynyl optionally substituted with one or more halogen atoms, Cι-6alkyl substituted with cyano or -C(=O)R 14 , Cι-6alkyloxy, Cι- 6 alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(Cι- 6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, - S(=O) p R 14 , -NH-S(=O) p R 14 , -C(=O)R 14 , -NHC(=O)H, -C(=O)NHNH 2 , -NHC(=O)R 14 ,-C(=NH)R 14 or aryl; p is 1 or 2; aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C]-6alkyl, C 3 - 7 cycloalkyl, Ci-6alkyloxy, cyano, nitro, amino, mono- or di(Cι- 4 alkyl)amino, polyhaloCi - alkyl and polyhaloC i . 6 alkyloxy ; aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, Cι- 6 alkyl, C 3 - 7 cycloalkyl, Ci-6alkyloxy, cyano, nitro, polyhaloC ι- 6 alkyl and polyhaloCι- 6 alkyloxy; Het 1 is a saturated, partially saturated or unsaturated (aromatic) heterocychc radical; said saturated heterocychc radical is selected from pyπolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl; said partially saturated heterocychc radical is selected from imidazolinyl, pyrazohnyl, pyrrohnyl, 4,5-dihydro-oxazolyl, 4,5-dihydro-thiazolyl, dihydrofuranyl, dihydrothienyl; and said aromatic heterocychc radical is selected from pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocychc radicals may optionally be substituted with C)- 4 alkyl; Het is a saturated, partially saturated or unsaturated (aromatic) heterocychc radical; said saturated heterocychc radical is selected from pyrrohdinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl wherein each of said saturated heterocychc radicals may optionally be substituted with an oxo group; said partially saturated heterocychc radical is selected from imidazolinyl, pyrazohnyl, pyrrohnyl, 4,5-dihydro-oxazolyl, 4,5-dihydro-thiazolyl, dihydrofuranyl, dihydrothienyl; and said aromatic heterocychc radical is selected from pyrrolyl, furanyl, thienyl, pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocychc radicals may optionally be substituted with hydroxy; provided that acetonitrile, [[2-bromo-4-(l-methylethyl)phenyl](4,6-dimethyl-2-pyrimidinyl)- amino]-; acetonitrile, [[2-bromo-4-(l-methylethyl)phenyl](4,6-dimethyl-2-pyrimidinyl)amino]- , monohydrochloride; 1, 2-ethanedi amine, N-[2-bromo-4-(l-methylethyl)phenyl]-N-(4,6-dimethyl-2- pyrimidinyl)-N',N'-diethyl; 1, 2-ethanedi amine, N-[2-bromo-4-(l-methylethyl)phenyl]-N-(4,6-dimethyl-2- pyrimidinyl)-N',N'-dimethyl are not included. 2. A compound as claimed in claim 1 wherein the (Aι)(A 2 )N- moiety is the covalently bonded form of the coπesponding inteπnediate of formula (A'ι)(A' 2 )N-H, said compound being represented by formula (A'ι)(A' 2 )N-R' (F) wherein said coπesponding inteπnediate of formula (A'ι)(A' 2 )N-H is a pyrimidine of formula a N-oxide, an addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein -b'=b -C(R 2a )=b 3 -b 4 = represents a bivalent radical of formula -CH=CH-C(R 2a )=CH-CH= (b-1) -Ν=CH-C(R 2a )=CH-CH= (b-2) -CH=N-C(R 2a )=CH-CH= (b-3) -N=CH-C(R 2a )=N-CH= (b-4) -N=CH-C(R 2a )=CH-N= (b-5) -CH=N-C(R 2a )=N-CH= (b-6); -N=N-C(R 2a )=CH-CH= (b-7); q is 0, 1, 2; or where possible q is 3 or 4; R 2a is cyano, aminocarbonyl, mono- or di(methyl)aminocarbonyl, Ci-6alkyl substituted with cyano, aminocarbonyl or mono- or di(methyl)aminocarbonyl, C 2 . 6 alkenyl substituted with cyano, or C 2 - 6 alkynyl substituted with cyano; each R 2 independently is hydroxy, halo, Cι_6alkyl optionally substituted with cyano or -C(=O)R 6 , C 3 . cycloalkyl, C 2 - 6 alkenyl optionally substituted with one or more halogen atoms or cyano, C 2 - 6 alkynyl optionally substituted with one or more halogen atoms or cyano, Cι_6alkyloxy, Ci-βalkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(Cι- 6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O) p R 6 , -NH-S(=O) p R 6 , -C(=O)R 6 , -NHC(=O)H, -C(=O)NHNH 2 , -NHC(=O)R 6 ,-C(=NH)R 6 or a radical of formula wherein each A) independently is N, CH or CR 6 ; and A 2 is NH, O, S or NR 6 ; p is 1 or 2; R R 66 iiss mmeetthhyyl, amino, mono- or dimethylamino or polyhalomethyl; and L, Y and Q are as defined in claim 1 for the intermediates of formula (II). 3. A compound as claimed in claim 1 or 2 wherein R 1 is Cι- 6 alkyl substituted with cyano, Cι-ι 2 alkyloxy, hydroxyCι- ]2 alkyloxy, Cι- 6 alkyloxyCι-ι 2 alkyloxy or aryl'carbonyloxyCι-ι 2 alkyloxy; -S(=O) 2 -R 8 with R 8 being Ci-βalkyl, aryl 1 or Het 1 ; C 7 -ι 2 alkylcarbonyl; R 9 R 10 N-Cι- 6 alkyloxycarbonylCι- 6 alkylcarbonyl with R 9 and R 10 each independently being selected from mono - or di(Cι- 4 alkyl)amino- Cι- 4 alkyl or R 9 and R 10 are taken together to form a bivalent radical of formula -CH 2 -CH 2 -O-CH 2 -CH 2 -; 4. A compound as claimed in any one of claims 1 to 3 wherein L is -X-R 3 wherein R 3 is 2,4,6-trisubstituted phenyl. 5. A compound as claimed in any one of claims 1 to 4 wherein Y is hydrogen, cyano, -C(=O)NH 2 or a halo atom. 6. A compound as claimed in any one of claims 1 to 5 wherein Q is hydrogen or NR 4 R 5 . 7. A compound as claimed in claim 1 wherein -a 1 =a 2 -a 3 =a 4 - represents a bivalent radical of formula -CH=CH-CH=CH- (a-1), R 2 is 4-cyano and n is 1. 8. A compound as claimed in any one of claims 1 to 7 wherein the intermediate of formula (II) or (H') is R1536844-[[4-amino-5-chloro-6-[(2,4,6-trimethylphenyl)- amino]-2-pyrin- dinyl]amino]benzonitrile; R1562044-[[5-chloro-4-[(2,4,6- trimethylphenyl)amino]-2-pyrirnidinyl]amino]benzonitrile;R1577534-[[5-bromo- 4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile; R1590254- [[4-amino-5-chloro-6-[(4-cyano-2,6-dimethylphenyl)amino]-2- pyrirnidinyl]amino]benzonitrile; R1597294-[[5-bromo-6-[(4-cyano-2,6- dimethylphenyl)amino]-2-pyrirmdinyl]amino]benzonitrile; R1648094-[[4-arnino- 5-chloro-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile; R1653354-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2- pyrimidinyl]amino]benzonitrile; R1476814-[[4-[(2,4,6-trimethylphenyl)amino]-2- pyrimidinyl]amino]benzonitrile; and R1529294-[[2-[(4-cyanophenyl)amino]-4- pyrimidinyl]amino]-3,5-dimethylbenzonitrile; a N-oxide, an addition salt, a quaternary amine and a stereochemically isomeric form thereof. 9. A compound as claimed in any one of claims 1 to 8 for use as a medicine. 10. The use of a compound for the manufacture of a medicament for the prevention or the treatment of HIV (Human Immunodeficiency Virus) infection, wherein the compound is a compound of formula (A I )(A 2 )Ν-R 1 (I) a N-oxide form, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein R 1 is Cι- 6 alkyl substituted with cyano, amino, mono- or di(C]- 4 alkyl)amino, nitro, Cι- ]2 alkyloxy, hydroxyCι-ι 2 alkyloxy, Cι- 6 alkyloxyCι-ι 2 alkyloxy, C|-6alkylcarbonyloxyCι-ι 2 alkyloxy, aryl 'carbon yl ox yCι-j 2 alkyloxy or -S(=O)-R 8 ; -S(=O) 2 -R 8 ; C 7 -ι 2 alkylcarbonyl; Cι-6alkyloxycarbonylCι- 6 alkylcarbonyl; hydroxycarbonylCι- 6 alkylcarbonyl; aryl'Ci-ealkyloxycarbonylCi-ealkylcarbonyl; Het'Ci- ό alkyloxycarbonyl- C i - 6 alkylcarbonyl ; R 9 R l °Ν-C i - 6 alkyloxycarbonylC i - 6 alkylcarbonyl ; (Aι)(A 2 )N- is the covalently bonded form of the coπesponding intermediate of formula (Aι)(A 2 )N-H, wherein said inteπnediate of formula (Aι)(A 2 )N-H is a pyrimidine of formula a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein -a'=a 2 -a 3 =a 4 - represents a bivalent radical of formula -CH=CH-CH=CH- (a-1); -Ν=CH-CH=CH- (a-2) -N=CH-N=CH- (a-3) -N=CH-CH=N- (a-4) -N=N-CH=CH- (a-5): n is 0, 1, 2, 3 or 4; and in case -a'=a 2 -a 3 =a 4 - is (a-1), then n may also be 5; each R 2 independently is hydroxy, halo, Cι_6alkyl optionally substituted with cyano or -C(=O)R 6 , C 3 . 7 cycloalkyl, C 2 - 6 alkenyl optionally substituted with one or more halogen atoms or cyano, C 2 - alkynyl optionally substituted with one or more halogen atoms or cyano, Cι_6alkyloxy, Cι.6alkyloxycarbonyl, carboxyl, cyano, aminocarbonyl, nitro, amino, mono- or di(Cι- 6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O) p R 6 , -NH-S(=O) p R 6 , -C(=O)R 6 , -NHC(=O)H, -C(=O)NHNH 2 , -NHC(=O)R 6 ,-C(=NH)R 6 or a radical of formula wherein each Ai independently is N, CH or CR 6 ; and A 2 is NH, O, S or NR 6 ; L is Ci-ioalkyl, C 2 .ιoalkenyl, C 2 -ιoalkynyl, C 3 - 7 cycloalkyl, whereby each of said groups may be substituted with one or two substituents independently selected from * C 3 - 7 cycloalkyl, * indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo, Cι-6alkyl, hydroxy, Cι_6alkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and Cι-6alkylcarbonyl, * phenyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined for R ; or L is -X J -R 3 or -X 2 -Alk-R n wherein R 3 and R 11 each independently are phenyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R 2 ; and X 1 and X 2 each independently are -NR 7 -, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)- or -S(=O) 2 -; Q represents hydrogen, Cι- 6 alkyl, halo, polyhaloC ι- 6 alkyl or -NR 4 R 5 ; and R 4 and R 5 are each independently selected from hydrogen, hydroxy, Ci-i2alkyl, Ci-i2alkyloxy, Cι.i2alkylcarbonyl, Ci.^alkyloxycarbonyl, Ci-i2alkylthiocarbonyl, aryl, amino, mono- or di(Cι.i2alkyl)amino, mono- or di(Ci-i2alkyl)aminocarbonyl wherein each of the aforementioned Cι-ι 2 alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, Ci-βalkyloxy, hydroxyCι- 6 alkyloxy, carboxyl, cyano, amino, imino, mono- or di(Ci-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O) p R 12 , -NH-S(=O) p R 12 , -C(=O)R 12 , -NHC(=O)H, -C(=O)NHNH 2 , -NHC(=O)R ,2 ,-C(=NH)R 12 , aryl and Het; or R 4 and R 5 taken together may form pyrrohdinyl, piperidinyl, morpholinyl, azido or mono- or di(Cι_i2alkyl)aminoCι- 4 alkanediyl; R 6 is methyl, amino, mono- or dimethylamino or polyhalomethyl; R is hydrogen; aryl; formyl; Ci-6alkylcarbonyl; Ci-6alkyl; Ci-6alkyloxycarbonyl; Cι_6alkyl substituted with formyl, Cι-6alkylcarbonyl, Cι-6alkyloxycarbonyl, Cι_6alkylcarbonyloxy; Cι.6alkyloxyCι_6alkylcarbonyl substituted with C i-6alkyloxycarbonyl ; R 8 is Cι- 6 alkyl, aryl 1 or Het'; R 9 and R 10 each independently are selected from hydrogen, Cι- 4 alkyl, aminoCι- 4 alkyl, R 9 and R 10 are taken together to form a bivalent radical of formula -CH 2 -CH 2 -Z-CH 2 -CH 2 - with Z being O, NR 13 , CH 2 , or a direct bond; R is methyl, amino, mono- or dimethylamino or polyhalomethyl; R 13 is hydrogen, aminoCι- alkyl, mono - or di(Cι- 4 alkyl)aminoCι- 4 alkyl; R 1 is methyl, amino, mono- or dimethylamino or polyhalomethyl; Y represents hydrogen, hydroxy, halo, Cι- 6 alkyl, C 3 - 7 cycloalkyl, C 2 - 6 alkenyl optionally substituted with one or more halogen atoms, C 2 - 6 alkynyl optionally substituted with one or more halogen atoms, Ci-6alkyl substituted with cyano or -C(=O)R 14 , Ci-6alkyloxy, Cι_6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(Cι^alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, - S(=O) p R 14 , -NH-S(=O) p R 14 , -C(=O)R 14 , -NHC(=O)H, -C(=O)NHNH 2 , -NHC(=O)R 14 ,-C(=NH)R 14 or aryl; p is 1 or 2; aryl 1 is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, Cι_6alkyl, C 3 . 7 cycloalkyl, Ci^alkyloxy, cyano, nitro, amino, mono- or di^ alky amino, polyhaloC ι- 6 alkyl and polyhaloC i - 6 alkyloxy; aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, Chalky!, C 3 - 7 cycloalkyl, Ci-6alkyloxy, cyano, nitro, polyhaloC ι-6alkyl and polyhaloC i- 6 alkyloxy; Het 1 is a saturated, partially saturated or unsaturated (aromatic) heterocychc radical; said saturated heterocychc radical is selected from pyrrohdinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl; said partially saturated heterocychc radical is selected from imidazolinyl, pyrazohnyl, pyπolinyl, 4,5-dihydro-oxazolyl, 4,5-dihydro-thiazolyl, dihydrofuranyl, dihydrothienyl; and said aromatic heterocychc radical is selected from pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocychc radicals may optionally be substituted with Cι- 4 alkyl; Het is a saturated, partially saturated or unsaturated (aromatic) heterocychc radical; said saturated heterocychc radical is selected from pyπolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl wherein each of said saturated heterocychc radicals may optionally be substituted with an oxo group; said partially saturated heterocychc radical is selected from imidazolinyl, pyrazohnyl, pyrrohnyl, 4,5-dihydro-oxazolyl, 4,5-dihydro-thiazolyl, dihydrofuranyl, dihydrothienyl; and said aromatic heterocychc radical is selected from pyrrolyl, furanyl, thienyl, pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocychc radicals may optionally be substituted with hydroxy. 11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound as claimed in any one of claims 1 to 8. 12. A process for preparing a pharmaceutical composition as claimed in claim 11 characterized in that a therapeutically effective amount of a compound as claimed in any one of claims 1 to 8 is intimately mixed with a pharmaceutically acceptable carrier. 13. A process for preparing a compound as claimed in claim 1, characterized by a) reacting an intermediate of formula (Aι)(A 2 )N-H with an intermediate of formula (ITf) in the presence of a suitable base and a suitable reaction-inert solvent (Aι)(A 2 )N H + R 1 — W, ► (A 1 )(A 2 )N R 1 (HI) (I) with Wi being a suitable leaving group, and R 1 and (Aι)(A 2 )N- are as defined in claim 1; b) reacting an intermediate of formula (Aι)(A 2 )N-H with an intermediate of formula (TV), and an intermediate of formula (V) in the presence of a suitable base and a suitable reaction-inert solvent (Aι)(A 2 )N— H + W 2 — * C— C r6 alkyl — 1 C?— W 2 + R 1a — OH (IV) (V) 1? : r6 alkyl i C?— N(A,)(A 2 ) (l-a) with W 2 being a suitable leaving group, (Aι)(A 2 )N-H is as defined in claim 1, and R la representing Cι- 6 alkyl, aryl'Cι- 6 alkyl, Het ] Cι- 6 alkyl or R 9 R 10 N-Cι- 6 alkyl; and, if desired, converting compounds of formula (I) into each other following art-known transformations; and further, if desired, converting the compounds of formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or conversely, converting the acid addition salt form into the free base by treatment with alkali; and, if desired, preparing stereochemically isomeric forms or N-oxide forms thereof. 14. A product containing (a) a compound as claimed in any one of claims 1 to 8, and (b) another antiretroviral compound, as a combined preparation for simultaneous, separate or sequential use in the treatment of HTN infection. 15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients (a) a compound as claimed in any one of claims 1 to 8, and (b) another antiretroviral compound.

Inventors: DE CORTE BART LIEVEN DANIEL, DE JONGE MARC RENE, HEERES JAN, JANSSEN PAUL ADRIAAN JAN, KAVASH ROBERT W, KOYMANS LUCIEN MARIA HENRICUS, KRIEF ALAIN, KUKLA MICHAEL JOSEPH, LUDOVICI DONALD WILLIAM, VAN AKEN KOEN JEANNE ALFONS, DE CORTE, BART, LIEVEN, DANIEL, DE JONGE, MARC, RENE, HEERES, JAN, JANSSEN, PAUL, ADRIAAN, JAN, KAVASH, ROBERT, W., KOYMANS, LUCIEN, MARIA, HENRICUS, KRIEF, ALAIN, KUKLA, MICHAEL, JOSEPH, LUDOVICI, DONALD, WILLIAM, VAN AKEN, KOEN, JEANNE, ALFONS
Applicants: AKEN KOEN JEANNE ALFONS VAN, CORTE BART LIEVEN DANIEL DE, HEERES JAN, JANSSEN PAUL ADRIAAN JAN, JANSSEN PHARMACEUTICA NV, JONGE MARC RENE DE, KAVASH ROBERT W, KOYMANS LUCIEN MARIA HENRICUS, KRIEF ALAIN, KUKLA MICHAEL JOSEPH, LUDOVICI DONALD WILLIAM, DE CORTE, BART, LIEVEN, DANIEL, DE JONGE, MARC, RENE, HEERES, JAN, JANSSEN PHARMACEUTICA N.V., JANSSEN, PAUL, ADRIAAN, JAN, KAVASH, ROBERT, W., KOYMANS, LUCIEN, MARIA, HENRICUS, KRIEF, ALAIN, KUKLA, MICHAEL, JOSEPH, LUDOVICI, DONALD, WILLIAM, VAN AKEN, KOEN, JEANNE, ALFONS
Application year: 2001
Main classification: C07D239
IPC codes: A61K31, A61K45, A61K47, A61P31, A61P43, C07D239, C07D401, C07D403